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Method and device for the synthesis of Artemisinin 
The present invention is directed to a method for converting dihydroartemisinic acid with 
singlet oxygen in a continuous flow reactor as a key step for producing artemisinin which 
has been used for a long time as anti-malaria drug, as well as to the continuous flow 
reactor for producing artemisinin. 
Malaria, caused by the protozoan parasite Plasmodium falciparum, remains a major global 
health problem that kills almost one million people each year. Artemisinin is currently the 
most effective treatment against multi-drug resistant Plasmodium species and artemisinin 
combination treatments (ACTs) are now first-line drugs (World Malaria Report 2010, WHO 
Geneva, 2010). Artemisinin belongs to the group of sesquiterpenes and has an 
uncommon trioxane ring structure and a peroxide bridge. Access to this sesquiterpene 
endoperoxide molecule relies on extraction and isolation from the leaves and blossoms of 
the plant Artemisia annua (sweet wormwood) that has been cultivated in many countries 
for that purpose (White, N. J. Science, 2008, 320, 330-334). The natural synthesis of 
artemisinin starts with isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl 
pyrophosphate to dihydroartemisinic acid and involves as intermediate product amorpha-
4,11-diene (Brown, G. D. Molecules, 2010, 15, 7603-7698). Total synthesis of artemisinin 
is too laborious to be considered viable for supplying the highly cost sensitive market. 
Artemisinic acid, a much less complex molecular precursor can be extracted from the 
same plant and can be produced in engineered Saccharomyces cerevisiae (Ro, O.-K., et 
a/., Nature, 2006, 440, 940-943). Therefore, artemisinic acid is a good starting point for 
the synthesis of the drug substance. Still, the conversion of artemisinic acid to artemisinin 
has proven a formidable challenge for chemists since a high-yielding and scalable low cost 
process for the construction of this highly complex molecule is needed. 
WO 2009/088404 A 1 discloses a synthesis for artemisinin starting from dihydroartemisinic 
acid (DHAA) 
0 
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which is in a first step converted to a dihydroartemisinic acid ester of the following formula 
0 
wherein R is an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, alkaryl or aralkyl group. The 
dihydroartemisinic acid ester is than reacted with a peroxidizing agent in order to obtain 
the dihydroartemisinic acid ester peroxide of the following formula 
0 
which is than converted to artemisinin by the reaction with oxygen. This four step 
synthesis is quite long and requires optimization especially for large scale synthesis in 
order to shorten this synthesis route, to reduce labor costs, purification efforts and to 
increase yield. 
Thus there is a need to provide a more efficient synthesis of artemisinin. 
Artemisinic acid and dihydroartemisinic acid, both bicyclic molecules, lack much of the 
complexity that imparts the biological activity to artemisinin, a sesquiterpene endoperoxide 
with a dense array of functional groups. Access to large quantities of artemisinic acid via 
engineered yeast (Ro, O.K. eta/. Nature, 2006, 440, 940-943), rendered artemisinic acid 
(1) an attractive starting material for chemical semi-synthesis of artemisinin. The 
conversion of artemisinic acid to artemisinin involves several challenging steps that were 
examined in the context several synthetic endeavors ( a) Roth, R. J.; Roth, N. A. United 
States Patent 4,992,561 1991 b) Reiling, K. K.; Renninger, N. S.; McPhee, D. J.; Fisher, K. 
J.; Ockey, D. A. International Patent WO 2006/128126 A1 2006. c) Roth, R. J.; Acton, N.J. 
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Chern. Edu. 1991, 68, 612-613. d) Roth, R. J.; Acton, N. A J. Nat. Prod. 1989, 52, 1183-
1185. e) Constantino, M. G.; Beltrame Jr. M.; da Silva, G. V. J. Syn. Cornrn. 1996, 26, 321-
329.). Current solutions to this problem are technically too complex for scale-up while 
meeting stringent cost targets. Photochemical transformations have the advantage that 
light is a relatively inexpensive and mild reagent, but were not used often for drug 
synthesis since they are hard to scale up. The distance light can penetrate through 
solutions is limited due to absorption and moving to larger reaction vessels greatly 
diminishes conversion and yield. 
Molecular oxygen is in this regard an attractive reagent due to its availability, low cost and 
negligible environmental impact. Singlet oxygen C02) is formed via dye-sensitized 
photoexcitation of triplet oxygen eo2) and facilitates heteroatom oxidations, ene reactions, 
as well as [4+2] and [2+2] cycloadditions ( a) Schweitzer, C.; Schmidt, R. Chern. Rev., 
2003, 103, 1685-1758. b) Hoffmann, N. Chern. Rev. 2008, 108, 1052-1103.). 
Consequently, 102 has been used for the synthesis of natural products and fragrances. 
Widespread use of 102 in conventional batch systems has been prevented by the need for 
specialized equipment to produce the reagent and technical challenges associated with 
scaling-up photochemical reactions and the low rate of mass transfer of oxygen gas. 
First approaches to the use of singlet oxygen C02) in the conversion of dihydroartemisinic 
acid have been made in recent years. In J. Org. Chern. 1992, 57, 3610 the conversion of 
dihydroartemisinic acid to artemisinin by use of singulet oxygen and methylene blue in 
photooxidation and subsequently use of trifluoroacetic acid in a batch process has been 
described. The same reaction and reaction conditions have been disclosed in US 
4992561 . These processes suffer from low yields and very long conversion times to 
finally get artemisinin. 
Also, artemisinic acid can be reduced to dihydroartemisinic acid using batch methods such 
as diimide on large scale (WO 2011/030223 A2). The three-step reaction sequence to 
convert dihydroartemisinic acid to artemisinin involving photochemically induced oxidation 
with singlet oxygen, acid-mediated Hock cleavage (a) Lange, J.-P.; Breed, A. J. M. Catal. 
Cornrn. 2002, 3, 25-28. b) Olah, G. A.; Parker, D. G.; Yoneda, N. Angew. Chern. Int. Ed. 
Engl. 1978, 17, 909-931) and oxidation with triplet oxygen (Chen, B.-C.; Zhou, P.; Davis, 
F. A.; Ciganek, E. Organic Reactions 2004, 64, 1-356) pose synthetic challenges which 
have not been solved, and hence those reactions remain to be performed with batch 
methods and all disadvantages associated therewith. 
In contrast, continuous flow reactors allow easy scale-up as no change in reactor size is 
required, provide a large surface-to-volume ratio that ensures efficient irradiation and 
enable precise control over the reaction time to minimize unwanted side reactions due to 
secondary photochemical reactions. In addition, continuous flow reactors improve safety 
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as reactive intermediates are quenched or further transformed immediately after 
production. Photochemical flow reactors have been explored for the generation and use of 
102. Although complete conversion was achieved in a short residence time, the process 
suffered from very low productivity, rendering the system inapplicable to use on industrial 
scale. Alternatively, this problem of low 02(g) mass transfer has been tackled by using 
supercritical carbon dioxide as a solvent, though this requires a highly specialized reaction 
set-up. 
Efficient oxidations are dependent on the solution concentration of 102, which in turn is 
proportional to the solution concentration of 302. Therefore, the productivity of the 
oxidation depends on the rate of mass transfer (d[302(soiJ]/dt) of 302(g) into the solution. 
Based on Fick's Law (Equation {1 }) the rate of mass transfer is determined by the liquid 
film transfer coefficient (KL), the specific surface area of the solution (a) and the oxygen 
deficit within the solution ([302(sol)]sad302(soi)D· 
When biphasic gas-liquid reactions are conducted at high flow rates, the specific surface 
areas in continuous flow reactors (up to 25300 m2/m3) can greatly exceed those attained in 
conventional batch reactors (up to 2000 m2/m3) due to flow pattern effects. To date, 
synthetic organic chemists have not taken full advantage of variations in the flow patterns 
of biphasic reactions. 
Intending to utilize continuous flow chemistry as a means to scale-up photochemical 
transformations the inventors examined the transformation of artemisinic acid (1) or 
dihydroartemisinic acid (2) to artemisinin (6) mindful of the necessity to create a simple, 
scalable and inexpensive process. 
Objective of the present invention is to provide a more efficient synthesis of artemisinin. 
The objective of the present invention is solved by the teaching of the independent claims. 
Further advantageous features, aspects and details of the invention are evident from the 
dependent claims, the description, the figures, and the examples of the present 
application. 
It was found that artemisinin can be prepared in a one continuous flow process from 
dihydroartemisinic acid (2) by the use of singlet oxygen. A simple continuous flow system 
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renders reactions involving singlet oxygen C02) practical for large scale synthetic 
synthesis of artemisinin. Efficient mass transfer and sufficient irradiation enable the 
straightforward production and use of 102 as a reagent in one continuous flow process for 
synthesis of artemisinin (6) starting from dihydroartemisinic acid (2). Dihydroartemisinic 
acid is commercially available from Honsea Sunshine Biotech Co., Ltd. or can be 
produced by a modified yeast (Zhang, Y. eta/. J. Bioi. Chern. 2008, 31, 21501-21508). 
Description 
Thus, the present invention is directed to a method for producing artemisinin (6) from 
dihydroartemisinic acid (2) comprising or consisting of the following steps: 
A) providing dihydroartemisinic acid (2) represented by the following formula 
0 
(2) 
B) performing in a continuous flow reactor the following reactions 
i) photooxidation of dihydroartemisinic acid (2) with singlet oxygen, 
ii) followed by an acid mediated cleavage and 
iii) subsequent oxidation with triplet oxygen 
in order to obtain artemisinin (6) of the following formula: 
0 
(6). 
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For this method it is preferred when all three steps i), ii) and iii) are performed in a 
continuous manner. 
In case a chemical synthesis of dihydroartemisinic acid (2) is desired, dihydroartemisinic 
acid (2) can be prepared by reducing artemisinic acid (1 ). Thus, dihydroartemisinic acid 
(2) can be obtained by reducing artemisinic acid (1) of the following formula 
to dihydroartemisinic acid (2). 
0 
(1) 
Thus the present invention is also directed to a method for producing artemisinin (6) from 
artemisinic acid (1) comprising the following steps: 
A) providing artemisinic acid (1) represented by the following formula 
0 
( 1) 





C) performing in a continuous flow reactor the following reactions 
PCT/EP2012/066800 
i) photooxidation of dihydroartemisinic acid (2) with singlet oxygen, 
ii) followed by an acid mediated cleavage and 
iii) subsequent oxidation with triplet oxygen 




For the afore-mentioned method it is preferred when all three steps i), ii) and iii) are 
performed in a continuous manner. 
The continuous flow reactor according to the present invention is a reactor, wherein at 
least the photooxidation of dihydroartemisinic acid (2) of the different reactions for the 
conversion of dihydroartemisinic acid (2) to artemisinin (6) can be performed in a 
continuous manner. The term "continuous" as used herein means, for instance, that there 
is provided a flow of a solution or mixture containing dihydroartemisinic acid (2) to the 
reactor which is continuously converted while flowing through the reactor system in the 
direction from an inlet to an outlet such that a reaction product can be continuously derived 
at the outlet of the reactor without dividing the reaction mixture into parts. The term 
"continuous" or "continuously" can be defined as a movement of the solution or mixture 
containing dihydroartemisinic acid (2) through the photochemical reactor while irradiated or 
while exposed to the light of the light source. This movement should only be in one 
direction, namely from the inlet to the outlet of the photochemical reactor or in other words 
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from the m1x1ng device or from the reservoir containing the starting materials (e.g. 
containing the solution of dihydroartemisinic acid (2) and optionally also the 
photosensitizer) to the feed of the acidic solution or to the reactor 15. The movement 
could also temporarily stop (velocity of the movement is zero) during a part of the time of 
the photooxidation. Thus during the time of the photooxidation, there must be a 
movement for a certain time in the direction described above. 
Thus, the term "continuous" as used herein refers to an endless flow of a solution or 
mixture containing dihydroartemisinic acid (2) through the photochemical reactor. Of 
course the flow through the photochemical reactor is theoretically endless and in practice 
will end after a certain time when for example the light source has to be replaced, the 
oxygen tank is empty or any part of the photochemical reactor has to be repaired or 
replaced or the reservoir of the dihydroartemisinic acid (2) starting material is empty. 
However in order to define the term "continuous" a theoretically endless flow of the 
solution or mixture containing dihydroartemisinic acid (2), oxygen and the photosensitizer 
can be assumed which flows through the photochemical reactor wherein this solution or 
mixture is exposed to the light generated by the light source. However, this flow does not 
require a steady or continuous flow rate (measured in volume per time). The flow rate can 
be constant, can be increased and decreased stepwise over the time, can follow a sinus 
curve, can be increased and decreased continuously (like a zig-zag curve), can be zero for 
a certain time or can be coupled to the conversion rate of the dihydroartemisinic acid (2), 
thus increasing the flow rate if the conversion rate is above a predefined limit or reducing 
the flow rate if the conversion rate is below a predefined limit or can also be arbitrarily 
adjusted. Thus, the term "continuous" as used herein means that the photooxidation is 
not performed batch-wise. Thus, the term "continuous" as used herein means that not 
definite volumes of the solution or mixture containing dihydroartemisinic acid (2) are 
exposed to the light of the light source over a certain time like a batch process does. The 
term "continuous" as used herein means that over a certain or predefined time the volume 
of the solution or mixture containing dihydroartemisinic acid (2) is not constant. This is 
because a solution or mixture containing dihydroartemisinic acid (2) enters as starting 
material the photochemical reactor, thus increasing the volume which is exposed to the 
light of the light source while most preferably the same volume of irradiated solution or 
mixture containing the photooxidation product of dihydroartemisinic acid (2) leaves the 
photochemical reactor within said time. The volume of the solution or mixture containing 
dihydroartemisinic acid (2) would only be constant if the flow rate is zero during the 
complete time of the photoreaction like in a batch process. Also, the volume of the 
solution or mixture containing dihydroartemisinic acid (2) is not supposed to be driven such 
that a product containing mixture after exposure of irradiation exits the reactor at the inlet. 
That is, the solution or mixture containing dihydroartemisinic acid (2) shall not be led 
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reverse in direction from the outlet to the inlet. The term "continuous" as used herein 
clearly distinguishes from a process where the solution or mixture containing 
dihydroartemisinic acid (2) is led into the reactor from the inlet in direction of the outlet, is 
then stopped and irradiated, and afterwards rather sucked out of the reactor back in 
direction of the inlet in order to collect a product containing mixture at the end of the inlet, 
just as it may be performed in batch-wise process. It may happen for the solution or 
mixture containing dihydroartemisinic acid (2) being driven reversely for test reasons, but 
only in order that the total direction of the continuous flow is driven towards the outlet, that 
is if driven shortly in reverse direction it must follow a longer period of flow in direction of 
the outlet.. Further, the term continuous may also comprise that solution or mixture 
containing dihydroartemisinic acid (2) is driven shortly once or several times or even 
fluctuating reversely if followed by a period where a bigger volume is driven in direction of 
the outlet. That is, the solution or mixture containing dihydroartemisinic acid (2) may be 
shortly driven reversely as long as no product exits the reactor at the inlet end and the total 
direction of all volume in the reactor is from inlet to outlet. 
Thus, the continuous flow as described herein may occur at a steady or a fluctuating flow 
rate. In case of a fluctuating flow the reaction mixture may also stop intermediately or 
periodically, hence the flow rate may fall down to zero. However, if once stopped the 
continuous flow has to continue in the direction from the inlet to the outlet of the reactor. 
"Continuous" as used herein also means that a desired product can be provided steadily 
without the necessity of starting a novel experiment or batch in order to increase the 
amount of the desired product after the reaction took place. The reaction set-up and the 
reactor design allow a steadily increasing amount of product when starting material is 
provided without upscaling the reactor dimensions. "Continuous" further means that if a 
starting material is constantly provided and converted, the conversion compound is 
consistently produced. 
In the continuous flow reactor according to the present invention at least the 
photooxidation of dihydroartemisinic acid (2) with singlet oxygen is performed in a 
continuous manner, while an acid mediated cleavage and subsequent oxidation with triplet 
oxygen may also be performed in a semi-batch manner or in a batch reactor. Thus at 
least the photooxidation in the photochemical reactor is performed continuously which 
means in a continuous manner as defined above, while the acid mediated cleavage [step 
ii)] and the oxidation with triplet oxygen [step iii)] do not necessarily have to be conducted 
in a continuous manner. However it is preferred that also step ii), namely the acid 
mediated cleavage and more preferred the acid mediated cleavage and step iii), namely 
the oxidation with triplet oxygen are conducted also in a continuous manner. The 
continuous manner of step ii) and step iii) can be different from the continuous manner of 
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step i). This means that different flow rates are normally used for the steps i), ii) and iii). 
Step ii) can normally be processed with the highest flow rate while step i) normally has the 
lowest flow rate of all three steps. 
Therefore, the continuous flow reactor of the present invention comprises at least a 
photochemical reactor, wherein the conversion of dihydroartemisinic acid (2) with singlet 
oxygen takes place continuously, i.e. in a continuous manner. 
As the photochemical reactor is comprised by the continuous flow reactor of the present 
invention every modification as being described below for the photochemical reactor also 
applies to the continuous flow reactor. 
The photochemical reactor for the production of artemisinin from dihydroartemisinic acid 
comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end. 
An alternative embodiment of the photochemical reactor for the production of artemisinin 
from dihydroartemisinic acid comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment exposed to the light source for irradiating the mixture of the 
solution of dihydroartemisinic acid and oxygen when the mixture passes the 
reactor compartment. 
A further alternative embodiment of the photochemical reactor for the production of 
artemisinin from dihydroartemisinic acid comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for carrying out the photooxidation and which is at least 
partially irradiated by the light source and which has at least one inlet for the 
solution of dihydroartemisinic acid and oxygen and at least one outlet for the 
solution after the photooxidation. 
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A further alternative embodiment of the photochemical reactor for the production of 
artemisinin from dihydroartemisinic acid comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for irradiation of the solution of dihydroartemisinic acid and 
the oxygen by the light source when the solution flows through the reactor 
compartment. 
Still a further alternative embodiment of the photochemical reactor for the production of 
artemisinin from dihydroartemisinic acid comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of the solution of dihydroartemisinic acid and 
oxygen on its one end and an outlet for the reacted products on the opposite 
end. 
The continuous flow reactor of the present invention comprises one of the afore-mentioned 
photochemical reactors. Even if not explicitly mentioned, the solution of 
dihydroartemisinic acid and the mixture of the solution of dihydroartemisinic acid and 
oxygen preferably comprise or contain a photosensitizer. 
The photochemical reactor or the continuous flow reactor preferably further comprises an 
oxygen source capable of providing oxygen above atmospheric pressure. The oxygen 
source is preferably an oxygen tank 4 with a manometer 3. The oxygen source can also 
be used to generate pressure so that the photooxidation according to step i) or all three 
steps i)-iii) can be performed under pressure. The pressure and especially the oxygen 
pressure increase the yield of the photooxidation product of step i) and thus leads finally to 
an increased yield of artemisinin. Thus it is preferred to carry out the photooxidation of 
step i) under pressure and especially under oxygen pressure. It is more preferred to carry 
out all three steps i) - iii) under pressure and especially under oxygen pressure. 
Therefore it is further preferred that oxygen for the provision of singlet oxygen is provided 
to the continuous flow reactor and/or the photochemical reactor above atmospheric 
pressure. 
Preferably the reactor compartment is a tubing 7. 
Also preferred as mixing device is aT-mixer valve. 
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The photochemical reactor further comprises preferably 
a box which is impervious to light with light reflecting inner walls and one opening 
through which the tubing 7 enters the box and another opening through which the 
tubing 7 leaves the box and 
multiple loops of the tubing 7 arranged in the inside of the box, wherein the tubing 7 
has an inlet for a mixture of dihydroartemisinic acid and oxygen on its one end before 
entering the box and an outlet for the reacted products on the opposite end after 
leaving the box. 
Preferably the photochemical reactor or the continuous flow reactor further comprises a 
cooling liquid and a chiller. 
Especially preferred is if the photochemical reactor or the continuous flow reactor further 
comprises a back pressure regulator 14. 
A continuous flow reactor of the present invention for the production of artemisinin from 
dihydroartemisinic acid comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
a feed for an acidic solution. 
The feed for an acidic solution can be incorporated into the continuous flow reactor of the 
present invention before or after the photochemical reactor as defined herein. That is, in 
one embodiment of the present invention the feed for an acidic solution is incorporated 
after the photochemical reactor, and if present before a reactor 15. In such an embodiment 
the feed for an acidic solution comprises separate reactor component. In another 
embodiment of the present invention the feed for an acidic solution is incorporated before 
the photochemical reactor. In such embodiment the feed for an acidic solution may be a 
separate reactor component to the feed of the other starting materials such as 
dihydroartemisinic acid, solvent and oxygen. In another embodiment the feed for an 
acidic solution may be incorporated into the feed for dihydroartemisinic acid, 
photosensitizer and solvent. That is, the continuous flow reactor of the present invention 
comprises one reactor component which provides dihydroartemisinic acid, solvent and the 
acid for the acid mediated cleavage simultaneously. In such an embodiment 
dihydroartemisinic acid, photosensitizer, solvent and acid are provided by one solution. 
wo 2013/030247 PCT/EP2012/066800 
13 
Thus, the acid for the acid mediated cleavage of the product of the photooxidation of 
dihydroartemisinic acid can be added before the photooxidation directly into the solution of 
dihydroartemisinic acid and the photosensitizer before or after the oxygen is added. In 
this case the acid for the acid mediated cleavage is already present during the 
photooxidation and the acid mediated cleavage starts to take place in the photochemical 
reactor or respectively the reactor compartment. In another embodiment the acid for the 
acid mediated cleavage is added after the photooxidation, i.e. after or respectively 
downstream the photochemical reactor or the reactor compartment and preferably before 
the reactor 15 (if present) or the acid for the acid mediated cleavage is added into the 
reactor 15 (if present) in order to perform the acid mediated cleavage within reactor 15 (if 
present). Thus there can be a feed for the acidic solution into reactor 15 (if present) or 
into the reaction solution after the photochemical reactor or after the reactor compartment 
and before reactor 15 (if present) or into the solution of dihydroartemisinic acid before the 
oxygen is added or into the solution of dihydroartemisinic acid after the oxygen is added 
and before this solution enters the photochemical reactor or the reactor compartment or 
into the reaction solution within the photochemical reactor or the reactor compartment. 
Thus, one embodiment of continuous flow reactor of the present invention for the 
production of artemisinin from dihydroartemisinic acid comprises or consists of: 
a feed for dihydroartemisinic acid, photosensitizer and solvent, 
an oxygen source, 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
a feed for an acidic solution. 
This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. The feed for 
dihydroartemisinic acid, photosensitizer and solvent may consist of three different 
supplies, wherein in each supply one of the components is provided, i.e. one supply for 
dihydroartemisinic acid, one supply for the photosensitizer and one supply for the solvent. 
It is also possible that the feed for dihydroartemisinic acid, photosensitizer and solvent 
consist of only one supply for a solution of dihydroartemisinic acid, photosensitizer and 
solvent. Also, it is possible that feed for dihydroartemisinic acid, photosensitizer and 
solvent combines two supplies for two components and has one separate supply, i.e. for 
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example a supply for dihydroartemisinic acid and solvent in the form of a 
dihydroartemisinic acid solution on the one hand and one supply for the photosensitizer. 
It is also possible that a solution of dihydroartemisinic acid in the solvent represents one 
supply and a solution of photosensitizer in the same or in another solvent represents a 
second supply. The feed for an acidic solution is preferably located downstream to the 
reactor compartment so that the acid is preferably added after the photooxidation. The 
reactor compartment is the part of the photochemical reactor or the part of the continuous 
flow reactor through which the solution or mixture containing dihydroartemisinic acid (2) 
flows while being irradiated by the light of the light source. 
The continuous flow reactor for the production of artemisinin from dihydroartemisinic acid 
downstream to the feed of starting materials comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end, and 
a feed for an acidic solution. 
This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. 
An alternative embodiment of the continuous flow reactor for the production of artemisinin 
from dihydroartemisinic acid downstream to the feed of starting materials comprises or 
consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment exposed to the light source for irradiating the mixture of 
dihydroartemisinic acid and oxygen when the mixture passes the reactor 
compartment, and 
a feed for an acidic solution. 
This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. 
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A further alternative embodiment of the continuous flow reactor for the production of 
artemisinin from dihydroartemisinic acid downstream to the feed of starting materials 
comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for carrying out the photooxidation and which is at least 
partially irradiated by the light source and which has at least one inlet for the 
solution of dihydroartemisinic acid and oxygen and at least one outlet for the 
solution after the photooxidation, and 
a feed for an acidic solution. 
This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. 
A further alternative embodiment of the continuous flow reactor for the production of 
artemisinin from dihydroartemisinic acid downstream to the feed of starting materials 
comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for irradiation of the solution of dihydroartemisinic acid and 
the oxygen by the light source when the solution flows through the reactor 
compartment, and 
a feed for an acidic solution. 
This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. 
Still a further alternative embodiment of the continuous flow reactor for the production of 
artemisinin from dihydroartemisinic acid downstream to the feed of starting materials 
comprises or consists of 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end, and 
a feed for an acidic solution. 
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This continuous flow reactor preferably also comprises a reactor 15 for performing the 
triplet oxygen oxidation and optionally for collecting the product. Most preferably the 
above continuous flow reactor further comprises a back-pressure regulator 14 in order to 
perform at least the photooxidation reaction [step i)] under pressure. 
All the above embodiments of the continuous flow reactor of the present invention may 
further comprise an additional reactor 16, or two additional reactors 16 and 17 and may 
also comprise a collection flask 18 for collecting the artemisinin containing solution. 
In a preferred embodiment the continuous flow reactor of the present invention for the 
production of artemisinin from dihydroartemisinic acid comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
a feed for an acidic solution, 
at least one reactor 15 for producing artemisinin or completing the synthesis of 
artemisinin, and 
optionally a collection flask 18 for collecting the artemisinin containing solution 
from at least one reactor 15. 
Suitable light sources are described below in detail. The mixing device is preferably aT-
mixer valve. The solution of dihydroartemisinic acid preferably contains at least one 
photosensitizer which are in detail described below. The mixing device is preferably 
located upstream the reactor compartment, i.e. before the inlet of the reactor 
compartment. The feed for an acidic solution is downstream the reactor compartment, i.e. 
after the outlet of the reactor compartment. The reactor 15 is also located downstream 
the reactor compartment, i.e. after the outlet of the reactor compartment. The reactor 15 
is connected to the reactor compartment and can be arranged downstream the feed for an 
acidic solution or the feed for an acidic solution goes into said reactor 15. The collection 
flask 18 is connected to the reactor 15 or if present to the reactor 16 which is then 
connected to the reactor 15 or if a third reactor 17 is present, the collection flask 18 is then 
connected to the reactor 17 which is connected to reactor 16 which is connected to reactor 
15. Most preferably the above continuous flow reactor further comprises a back-pressure 
regulator 14 in order to perform at least the photooxidation reaction [step i)] under 
pressure. This back-pressure regulator 14 can be positioned at the end or at the outlet of 
the reactor compartment, or at the outlet of the photochemical reactor, or before the feed 
for an acidic solution, or after the reactor 15, or if present after the reactor 16, or if present 
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after the reactor 17, or if present after the collection flask 18. In addition one or more 
further pressure regulators 14a/14b/14c might be positioned at the afore-mentioned 
positions before the back-pressure regulator 14. 
As used herein the term "before" means upstream the reaction flow and the term "after" 
means downstream the reaction flow. The reaction flow is, of course, from the feed of the 
starting materials to the artemisinin as final product. 
As defined herein the "back-pressure regulator 14" is the last pressure regulator 
downstream in the continuous flow reactor. 
Thus, the afore-mentioned continuous flow reactor might further comprise 
a second reactor 16 downstream to the first reactor 15 or 
a second reactor 16 downstream to the first reactor 15 and a third reactor 17 
downstream to the second reactor 16. 
Most preferably, the continuous flow reactor further comprises a back-pressure regulator 
14 downstream to the reactor 15 or downstream to the reactor 16 or downstream to the 
reactor 17 and most preferably downstream to the last reactor of the reactors 15, 16 (if 
present) and 17 (if present). Thus it is preferred that after the last reactor the back-
pressure regulator 14 is located so that all reaction steps i) - iii) can be performed under 
pressure. Thus in this case the whole continuous flow reactor is operated under pressure 
and preferably under oxygen pressure. In addition or instead of the back-pressure 
regulator 14 other pressure regulators 14a (in case of one additional pressure regulator 
14a; in case of a second 14a and 14b, in case of a third 14a, 14b and 14c, and so forth) 
can be present within the continuous flow reactor which are preferably placed after (i.e. 
downstream) the reactor compartment or after (i.e. downstream) the photochemical 
reactor and/or after (i.e. downstream) the feed for an acidic solution and/or after (i.e. 
downstream) the reactor 15 and/or after (i.e. downstream) the reactor 16 (if present) 
and/or after (i.e. downstream) the reactor 17 (if present) and/or after (i.e. downstream) the 
collection flask 18 (if present). 
By introduction of other pressure regulators 14a/14b/14c preferably between different 
reactors of the continuous flow reactor, wherein in each different reactions for the 
conversion of dihydroartemisinic acid to artemisinin take place, it is possible to run each 
different reaction at a specific, adjustable pressure, preferable oxygen pressure. It is clear 
to the skilled person that the initial pressure in the continuous flow may be the highest in 
the whole reactor which decreases over the length of the reactor or with the reaction steps 
i), ii) and iii). Such a decrease of pressure may occur steadily or in steps by adjusting the 
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other pressure regulators 14a/14b/14c accordingly, if present. 14a/14b/14c means 14a 
or 14a and 14b or 14a and 14b and 14c, i.e. one additional pressure regulator is present 
or two or three additional pressure regulators are present. The additional pressure 
regulators 14a/14b/14c are in addition to the back-pressure regulator 14 which is 
downstream the last pressure regulator. In case an oxygen tank 4 is used as oxygen 
source, this oxygen tank 4 has of course a manometer 3 for pressure regulation. 
However this manometer 3 is not counted as a pressure regulator 14a/14b/14c. 
However, the continuous flow reactor of the present invention may also be designed that 
by corresponding setting of the pressure regulators it may occur a higher pressure in a 
middle compartment or at the end of the reactor in comparison to the initial pressure at the 
inlet of the photochemical reactor. In order to have a freely adjustable pressure, 
preferably an oxygen pressure, more than one high pressure gas sources, e.g. for oxygen, 
for oxygen mixtures such as air, or other gases such as nitrogen or non-oxygen containing 
gas mixture, may be incorporated into the continuous flow reactor of the present invention. 
In a preferred embodiment of the present invention the continuous flow reactor is designed 
such that different pressures, preferably oxygen pressures (such as pure oxygen partial 
pressure and air partial pressure), being precisely adjustable can be applied for the 
photooxidation of dihydroartemisinic acid with singlet oxygen, for the acid mediated Hock 
cleavage and for the oxidation with triplet oxygen, even in case all three reactions are 
performed in a continuous manner. 
Also in the preferred case the entire production of artemisinin from dihydroartemisinic acid 
is performed in a continuous manner under increased pressure from the initial gas inlet to 
e.g. a back pressure regulator 14 at the end of a first reactor 15 or a second reactor 16 or 
a third reactor 17 or even the collection flask 18, the pressure may drop steadily over the 
length of the reactor, especially in case the reactor in mainly a tubing 7. 
Thus, in especially preferred embodiments of the continuous flow reactor of the present 
invention the continuous flow reactor comprises a back pressure regulator 14. These 
embodiments may further comprise additional pressure regulators 14a/14b/14c. One, 
two, three, four, five or more additional pressure regulators can be present. In case 
further pressure regulators are present, they are positioned at places different from the 
position of the back pressure regulator 14. Thus it is possible but not preferred that two 
pressure regulators are at the same position. In case two pressure regulators are 
present, namely 14 and 14a, the pressure regulator 14a is preferably positioned after the 
photochemical reactor or the reactor compartment and before the feed for the acidic 
solution and the back pressure regulator 14 after the reactor wherein the triplet oxygen 
oxidation is performed and if present before the collection flask 18. Alternatively, in case 
two pressure regulators are present, namely 14 and 14a, as well as a first reactor 15 it is 
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specifically preferred that the pressure regulator 14a is positioned before the first reactor 
15 which is positioned before the back pressure regulator 14 which is positioned, if 
present, before the collection flask 18. In case three pressure regulators are present, 
namely 14, 14a and 14b, the pressure regulator 14a is preferably positioned after the 
photochemical reactor or the reactor compartment and before the feed for the acidic 
solution, the pressure regulator 14b after the reactor 15 and before the reactor wherein the 
triplet oxygen oxidation is performed and the back pressure regulator 14 after the reactor 
wherein the triplet oxygen oxidation is performed and if present before the collection flask 
18. Alternatively, in case three pressure regulators are present, namely 14, 14a and 14b, 
as well as a first reactor 15 and a second reactor 16 it is specifically preferred that the 
pressure regulator 14a is positioned before the first reactor 15 which is positioned before 
the pressure regulator 14b which is positioned before the second reactor 16 which is 
positioned before the back pressure regulator 14 which is positioned, if present, before the 
collection flask 18. 
In case four pressure regulators are present, namely 14, 14a, 14b and 14c, the pressure 
regulator 14a is preferably positioned after the photochemical reactor or the reactor 
compartment and before the feed for the acidic solution, the pressure regulator 14b after 
the reactor 15 and before the reactor 16, the pressure regulator 14c after the reactor 16 
and before the reactor 17, and the back pressure regulator 14 after the reactor 17 and if 
present before the collection flask 18. Thus it is especially preferred that one pressure 
regulator is positioned after the photochemical reactor or the reactor compartment and 
before the feed for the acidic solution and that another pressure regulator is positioned 
before the reactor wherein the triplet oxygen oxidation is performed and a third pressure 
regulator after the reactor wherein the triplet oxygen oxidation is performed so that at least 
the photooxidation with singlet oxygen and also the oxidation with triplet oxygen can be 
performed under pressure. In such embodiment the pressure for the oxidation with singlet 
oxygen is generated by the oxygen source, preferably an oxygen tank 4 with a manometer 
3 and the pressure for the oxidation with triplet oxygen is generated by another oxygen 
source which could also be an oxygen tank with a manometer or just air introduced into 
the reactor under pressure. Alternatively, in case four pressure regulators are present, 
namely 14, 14a, 14b and 14c, as well as a first reactor 15 and a second reactor 16 and a 
third reactor 17 it is specifically preferred that the pressure regulator 14a is positioned 
before the first reactor 15 which is positioned before the pressure regulator 14b which is 
positioned before the second reactor 16 which is positioned before the pressure regulator 
14c which is positioned before the third reactor 17 which is positioned before the back 
pressure regulator 14 which is positioned, if present, before the collection flask 18. 
In a further especially preferred embodiment the pressure over the whole continuous flow 
reactor or the pressure for the reaction steps i), ii) and iii) is generated by the oxygen 
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source. This does not necessarily lead to an identical pressure for all three reaction 
steps, because the pressure drops over the components of the continuous flow reactor. 
However in this especially preferred embodiment the highest pressure is used for the 
photooxidation reaction while the pressure is dropped when performing the acidic 
cleavage and is probably dropped again when performing the triplet oxygen oxidation. 
However these pressure drops might be small and might be in a range of 10 hPa to 10000 
hPa, preferably in the range from 100 hPa to 6000 hPa, more preferably in the range from 
500 hPa to 5000 hPa and still and more preferably in the range from 1000 hPa to 4000 
hPa. 
The pressure drop over the length of the tubing 7 depends on various parameters and can 
11p = 8J1Lq 
be calculated in the laminar flow regime by the following formula Trr 4 , whereby 1..1 is 
the dynamic viscosity of the solvent, Lis the length of the tubing, q the volumetric flow rate 
and r the inner radius of the tube. 
Taking into account the roughness of the tube the actual pressure drop is higher. 
However, depending on the length of the reactor and the density of connections between 
reactor parts it is well possible to uphold an increased pressure over the entire length over 
the reactor, even in case for an embodiment wherein the whole conversion of 
dihydroartemisinic acid to artemisinin is performed continuously and under increased 
pressure from the oxygen or gas feed up to the final back pressure regulator 14. 
Accordingly, in one embodiment for the continuous flow reactor with a reactor setup as 
given in example 12 comprising a back pressure regulator 14 set to 8 bar being attached 
to the exit of the reactor, a pressure within the reactor is established of about 10-12 bar 
after the pumping unit and before entering the photochemical reactor. In such 
embodiment the pressure drop of the whole reactor system is about 2-4 bar. 
However, by introduction of pressure regulator 14a between the pumping unit and the 
back pressure regulator it is possible to change the profile of the pressure drop within the 
reactor and adjust the respective pressure to the different reactions taking place. 
In a preferred embodiment of the present invention the photooxidation of step i) is carried 
out under pressure. In a very preferred embodiment of the present invention the reaction 
steps i), ii) and iii) are conducted or carried out under pressure. Thus the photooxidation 
with singlet oxygen, the acid mediated cleavage and the oxidation with triplet oxygen are 
preferably performed under a pressure of above 8000 hPa, more preferably above 10000 
hPa and still more preferably above 12000 hPa. The photooxidation reaction with singlet 
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oxygen [step i)] is preferably carried out under pressure of 5000 hPa - 50000 hPa, 
preferably 7000 hPa - 40000 hPa, more preferably 8000 hPa - 30000 hPa, still more 
preferably 9000 hPa - 25000 hPa, still more preferably 10000 hPa - 20000 hPa, still more 
preferably 11000 hPa - 19000 hPa, still more preferably 12000 hPa - 18000 hPa, still 
more preferably 13000 hPa - 17000 hPa, and most preferably 14000 hPa - 16000 hPa. 
The acid mediated cleavage is preferably performed under a pressure of 1000 hPa -
15000 hPa, more preferably 2000 hPa - 14000 hPa, more preferably 3000 hPa - 13000 
hPa, more preferably 4000 hPa - 12000 hPa, more preferably 5000 hPa - 11000 hPa, 
more preferably 6000 hPa- 10000 hPa, and still more preferably 7000 hPa- 9000 hPa. 
The oxidation with triplet oxygen is preferably conducted at a pressure of 1000 hPa -
15000 hPa, more preferably of 2000 hPa - 14000 hPa, more preferably of 3000 hPa -
13000 hPa, more preferably of 4000 hPa - 12000 hPa, more preferably of 5000 hPa -
11000 hPa, more preferably of 6000 hPa- 10000 hPa, and most preferably of 7000 hPa-
9000 hPa. 
The initial pressure with which the oxygen is fed into the system for generating the singlet 
oxygen is preferably between 8000 hPa and 15000 hPa and more preferably between 
9000 hPa and 14000 hPa, and most preferably between 10000 hPa and 13000 hPa. 
The pressure drop over the three steps i), ii) and iii) is preferably between 1000 hPa and 
10000 hPa, more preferably between 1500 hPa and 6000 hPa and still more preferably 
between 2000 hPa and 4000 hPa. 
Thus, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
- a light source 11, 
- a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
- a reactor compartment exposed to the light source for performing the 
photooxidation, 
- pressure regulator 14a 
- at least one reactor 15, and 
- a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. 
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Also, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
pressure regulator 14a, 
one reactor 15, 
pressure regulator 14b, 
a second reactor 16, 
pressure regulator 14c, 
a third reactor 17, and 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. 
Also, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
pressure regulator 14a, 
a feed for an acidic solution, 
one reactor 15, 
pressure regulator 14b, 
a second reactor 16, 
pressure regulator 14c, 
a third reactor 17, and 
a back-pressure regulator 14. 
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The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. 
Also, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
pressure regulator 14a, 
a feed for an acidic solution, 
one reactor 15, 
pressure regulator 14b, 
a second reactor 16, 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. 
Also, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
pressure regulator 14a, 
a feed for an acidic solution, 
one reactor 15, 
a back-pressure regulator 14. 
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The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. 
Further, the continuous flow reactor of the present invention preferably comprises or 
consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
a feed for an acidic solution, 
at least one reactor 15, and 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment comprises one reactor 15 and may further 
comprise a collection flask 18 for collecting the artemisinin containing solution or a device 
for continuous separation of artemisinin (6) and optionally one further reactor 16 or 
optionally two further reactors 16 and 17. Moreover this embodiment may further 
comprise additional pressure regulators 14a/14b/14c. 
Also, the continuous flow reactor of the present invention preferably comprises or consists 
of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment exposed to the light source for performing the 
photooxidation, 
a feed for an acidic solution, 
at least one reactor 15, 
a back-pressure regulator 14, and 
a device for continuous separation of artemisinin (6). 
In a preferred embodiment of the present invention the device for continuous separation of 
artemisinin (6) can be simulated moving bed chromatography columns or reactor parts for 
continuous crystallization. This embodiment comprises one reactor 15 and may further 
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comprise a collection flask 18 for collecting the artemisinin containing solution or a device 
for continuous separation of artemisinin (6) and optionally one further reactor 16 or 
optionally two further reactors 16 and 17. Moreover this embodiment may further 
comprise additional pressure regulators 14a/14b/14c. 
In another preferred embodiment of the present invention the continuous flow reactor 
comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment exposed to the light source for irradiating the mixture of 
dihydroartemisinic acid and oxygen when the mixture passes the reactor 
compartment, 
at least one reactor 15, and 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). This embodiment comprises one reactor 15 and may further comprise a 
collection flask 18 for collecting the artemisinin containing solution or a device for 
continuous separation of artemisinin (6) and optionally one further reactor 16 or optionally 
two further reactors 16 and 17. Moreover this embodiment may further comprise 
additional pressure regulators 14a/14b/14c. In this preferred embodiment of the present 
invention the device for continuous separation of artemisinin (6) can be simulated moving 
bed chromatography columns or reactor parts for continuous crystallization. 
Yet in another preferred embodiment of the present invention the continuous flow reactor 
comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for carrying out the photooxidation and which is at least 
partially irradiated by the light source and which has at least one inlet for the 
solution of dihydroartemisinic acid and oxygen and at least one outlet for the 
solution after the photooxidation, 
at least one reactor 15, and 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
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artemisinin (6). This embodiment comprises one reactor 15 and may further comprise a 
collection flask 18 for collecting the artemisinin containing solution or a device for 
continuous separation of artemisinin (6) and optionally one further reactor 16 or optionally 
two further reactors 16 and 17. Moreover this embodiment may further comprise 
additional pressure regulators 14a/14b/14c. In this preferred embodiment of the present 
invention the device for continuous separation of artemisinin (6) can be simulated moving 
bed chromatography columns or reactor parts for continuous crystallization. 
Even yet in another preferred embodiment of the present invention the continuous flow 
reactor comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment for irradiation of the solution of dihydroartemisinic acid and 
the oxygen by the light source when the solution flows through the reactor 
compartment, 
at least one reactor 15, and 
a back-pressure regulator 14. 
The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). This embodiment comprises one reactor 15 and may further comprise a 
collection flask 18 for collecting the artemisinin containing solution or a device for 
continuous separation of artemisinin (6) and optionally one further reactor 16 or optionally 
two further reactors 16 and 17. Moreover this embodiment may further comprise 
additional pressure regulators 14a/14b/14c. In this preferred embodiment of the present 
invention the device for continuous separation of artemisinin (6) can be simulated moving 
bed chromatography columns or reactor parts for continuous crystallization. 
Still yet in another preferred embodiment of the present invention the continuous flow 
reactor comprises or consists of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end, 
at least one reactor 15, and 
a back-pressure regulator 14. 
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The continuous flow reactor of this embodiment may further comprise a collection flask 18 
for collecting the artemisinin containing solution or a device for continuous separation of 
artemisinin (6). This embodiment comprises one reactor 15 and may further comprise a 
collection flask 18 for collecting the artemisinin containing solution or a device for 
continuous separation of artemisinin (6) and optionally one further reactor 16 or optionally 
two further reactors 16 and 17. Moreover this embodiment may further comprise 
additional pressure regulators 14a/14b/14c. In this preferred embodiment of the present 
invention the device for continuous separation of artemisinin (6) can be simulated moving 
bed chromatography columns or reactor parts for continuous crystallization. 
Moreover the continuous flow reactor preferably further comprises an oxygen source 
capable of providing oxygen above atmospheric pressure. Such oxygen source is 
preferably an oxygen tank 4 with a manometer 3. 
An important component of the continuous flow reactor in the reactor compartment is in a 
preferred embodiment a tubing 7. Such a tubing 7 is preferably wrapped in multiple loops, 
or wrapped around a transparent support which does not hinder the light to go through so 
that all parts of the loops or all parts of the tubing 7 is exposed to the light of the light 
source or is wrapped around the light source. 
In another preferred embodiment the tubing 7 consists of a plurality of transparent plates 
such as glass plates arranged over each other between which the solution or mixture of 
dihydroartemisinic acid flows while being exposed to the light of the light source. 
In a still further preferred example the tubing 7 is in the form of a cylinder or a double-
walled cylinder arranged around the light source and the solution or mixture of 
dihydroartemisinic acid flows through that cylinder or within the walls of the doubled-walled 
cylinder while being exposed to the light of the light source. One or more cooling cylinder 
might be present around the light source and/or around or within the cylinder or double-
walled cylinder. 
The reactor compartment is this part of the continuous flow reactor or more specific of the 
photochemical reactor, wherein the photooxidation is performed. Therefore, the reactor 
compartment refers to the part or the parts of the continuous flow reactor which is/are 
exposed to the light of the light source and through which the mixture or solution of 
dihydroartemisinic acid together with the oxygen flows and wherein the singlet oxygen is 
generated. Thus, the reactor compartment can be a tubing 7 or preferably comprises a 
tubing 7 which is exposed to the light of the light source and through which the mixture or 
solution of dihydroartemisinic acid together with the oxygen flows and wherein the singlet 
oxygen is generated. The reactor compartment is designed in a way that the tubing 7 is 
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exposed to the light of the light source in the best possible manner. Preferably the reactor 
compartment has non-transparent outer walls or a non-transparent housing wherein the 
light source is located. The inner walls of the reactor compartment are preferably light 
reflecting so that as much as possible of the generated light of the light source can be 
used for the photooxidation. 
In general, a reactor component as used herein refers to a section of the continuous flow 
reactor, from the feed of a certain starting material to the outlet of product, wherein certain 
actions or operations for the conversion of dihydroartemisinic acid (2) to artemisinin (6) 
take place and comprise all reactor parts which are involved in these actions or operations. 
The reactor compartment is therefore a specific form of a reactor component. If the 
continuous flow reactor is seen as a long sequence of different reactor parts which the 
starting materials alone or in a mixture pass along, section can almost be taken literally in 
that certain parts are figuratively cut out of the sequence and defined by their function to 
the reaction. 
For example, reactor components of the continuous flow reactor of the present invention 
are reactor parts for the following actions: 
provision of the starting materials, 
mixing of the starting materials, 
irradiation of a solution of dihydroartemisinic acid, sensitizer, solvent and oxygen, 
mixing with acid, 
reaction of the acid for the Hock cleavage, 
oxidation with triplet oxygen for the formation of artemisinin. 
According to the present invention a reactor component may comprise the physical reactor 
parts for more than one function for enabling the different reactions for the conversion of 
dihydroartemisinic acid (2) to artemisinin (6). One reactor component may only comprise 
these parts of the continuous flow reactor of the present invention where the Hock 
cleavage takes place. However, another reactor component may comprise all parts where 
the conversions take place that the material flow undergoes after the irradiation of the light 
source. 
The reactor component of the continuous flow reactor for performing the photooxidation 
reaction is the reactor compartment with all reactor parts that are irradiated by the light 
source and having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end. It is also possible that the 
photochemical reactor as defined herein with all different possible specifications may be a 
reactor compartment of the continuous flow reactor of the present invention. 
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Thus the term "reactor compartment" refers to the reactor parts that are irradiated by the 
light source. Within the reactor compartment the photooxidation reaction with singlet 
oxygen is performed under irradiation by the light source. Thus the mixture of solvent, 
dihydroartemisinic acid, photosensitizer and oxygen flows through the reactor 
compartment wherein the photooxidation reaction with singlet oxygen [step i)] is 
performed. The reactor compartment through which the mixture flows which is exposed 
to the light of the light source has the form of a tube, coil, cylinder, double-wall cylinder, 
multi-walled cylinder, tubing, duct, pipe, spiral, helix, spiral coil, zig-zag coil, board, 
fluidized bed, multi-layered fluidized bed, pool, vessel, tank, basin or the like. The reactor 
compartment has a form so that the mixture to be irradiated which flows through the 
reactor compartment is almost all the time exposed to the light of the light source when 
flowing through the reactor compartment. 
According to the continuous flow reactor of the present invention the reactor compartment 
may adopt any suitable shape, preferably those specified above wherein the mixture of 
solvent, dihydroartemisinic acid, photosensitizer and oxygen can be well irradiated, 
preferably with a high surface area. For example, in case of a multi-walled cylinder 
different cylinders can be arranged around the at least one light source in the middle of the 
assembly which are preferably made of glass, more preferably of pressure proof glass, 
such that the light can easily be irradiated without significant loss of intensity on the 
solution running through the cylinder which can further be processed under increased 
pressure, preferably oxygen pressure. Particularly, in a doubled-walled or multiple-walled 
cylinder the solution or mixture of dihydroartemisinic acid flows more than once past the 
light source and experiences an increased retention time. Also, between the walls or at 
one side of and/or around or within one cylinder a cooling cylinder may be incorporated. 
Also, a second light source can be incorporated at the circumference of the cylinder. 
Such assembly may also be adapted for spiral, helix, spiral coil or zig-zag coil, wherein 
these coil reactors are arranged around or in vicinity to the light source. Also, those coils 
are preferably made of glass or any other suitable transparent material. Also, the reactor 
compartment may consist of or comprise a plane board, fluidized bed or a multi-layered 
fluidized bed e.g. in the form of multiple layers of glass or any suitable transparent polymer 
assembled vertically over each other, whereon or where in between the layers the mixture 
of solvent, dihydroartemisinic acid, photosensitizer and oxygen can flow, and can be 
irradiated. In case of a multi-layered fluidized bed two consecutive layers are connected to 
each other intermittently at alternating ends such that the layers form a serpentine 
assembly in a cross-section view. In such an assembly the mixture of solvent, 
dihydroartemisinic acid, photosensitizer and oxygen can be well irradiated from below 
and/or above while flowing through the gaps of the fold-like glass layer assembly. In such 
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an assembly one or more cooling systems can be incorporated at the bottom, the top 
and/or at the sides of the compartment. 
The reactor compartment may also be a pipe, duct, pool, tank, basin or vessel through 
which the mixture of solvent, dihydroartemisinic acid, photosensitizer and oxygen flows 
from the inlet to the outlet, and wherein the light source is immersed into the solution such 
that the mixture of solvent, dihydroartemisinic acid, photosensitizer and oxygen flows 
along the light source; the light source preferably comprising a cooling cylinder. 
Thus the function of the reactor compartment is to expose the mixture flowing through that 
reactor compartment as much and as long as possible to the light source for irradiating the 
mixture of dihydroartemisinic acid, photosensitizer and oxygen. 
According to the present invention there may also be reactor compartments specifically 
designed for certain embodiments of the continuous flow reactor. For example, for the 
immersion well assembly, there may be a reactor compartment 
for irradiating the mixture of dihydroartemisinic acid and oxygen having an 
immersion well and a filter, or 
for carrying out the photooxidation having an inlet to the immersion well for a 
mixture of dihydroartemisinic acid and oxygen and an outlet from the immersion 
well, 
comprising tubing 7 being wrapped around the immersion well and being exposed 
to the light source for performing the photooxidation. 
For the box assembly there may be a reactor compartment 
in the form of a tubing 7 being wrapped around a transparent plate, wherein the 
reactor compartment is exposed to the light source for performing the 
photooxidation, 
in the form of a tubing 7 being wrapped around a transparent plate being at least 
partially irradiated by the light source and having an inlet for the mixture of 
dihydroartemisinic acid and oxygen on its one end and an outlet for the reacted 
products on the opposite end. 
For the cooled box assembly there may be a reactor compartment 
in the form of a tubing 7 being wrapped around a transparent plate having an inlet 
for the mixture of dihydroartemisinic acid and oxygen on its one end and an outlet 
for the reacted products on the opposite end, wherein the transparent plate with the 
wrapped tubing is immersed into a cooling liquid, 
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in the form of a tubing 7 being wrapped around a transparent plate being at least 
partially irradiated by the light source. 
For the cylinder assembly there may be a reactor compartment 
in the form of a transparent cylinder being positioned around a light source having 
an inlet for the mixture of dihydroartemisinic acid and oxygen on its one end and an 
outlet for the reacted products, 
in the form of a multiple-walled cylinder while being exposed to the light of the light 
source, wherein the mixture of dihydroartemisinic acid and oxygen flows between 
the walls and wherein the walls are made of transparent material and wherein the 
mixture of dihydroartemisinic acid and oxygen is exposed to the light of the light 
source in each gap between the walls of the multiple-walled cylinder. 
Thus, for example one aspect of the present invention is directed to a continuous flow 
reactor comprising or consisting of: 
a light source 11, 
a mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
a reactor compartment in the form of a tubing 7 or in form of transparent plates 
arranged over each other or in form of a cylinder or double-walled cylinder, 
wherein the reactor compartment is exposed to the light source for performing 
the photooxidation, 
a feed for an acidic solution, 
at least one reactor 15, 
a back-pressure regulator 14, and 
a collection flask 18 for collecting the artemisinin containing solution. 
Also preferred is the reactor component which comprises a reactor compartment in the 
form of a tubing 7 in a box which is impervious to light with light reflecting inner walls and 
one opening through which the tubing 7 enters the box and another opening through which 
the tubing 7 leaves the box and multiple loops of the tubing 7 are arranged in the inside of 
the box, wherein the tubing 7 has an inlet for a mixture of dihydroartemisinic acid and 
oxygen on its one end before entering the box and an outlet for the reacted products on 
the opposite end after leaving the box. 
Moreover it is preferred that continuous flow reactor further comprises a cooling liquid 
and/or a chiller. The cooling liquid and/or the chiller shall cool the solution or mixture of 
dihydroartemisinic acid during the photooxidation. 
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Another preferred embodiment of the present invention is directed to a method for 
producing artemisinin (6) from dihydroartemisinic acid (2) comprising or consisting of the 
following steps: 
A) providing dihydroartemisinic acid (2) represented by the following formula 
B) performing the following reactions 
0 
(2) 
i) photooxidation of dihydroartemisinic acid (2) with singlet oxygen in a 
continuous manner in a photochemical reactor, 
ii) followed by an acid mediated cleavage and 
iii) subsequent oxidation with triplet oxygen 
in order to obtain artemisinin (6) of the following formula: 
0 
(6). 
In case a chemical synthesis of dihydroartemisinic acid (2) is desired, dihydroartemisinic 
acid (2) can be prepared by reducing artemisinic acid (1 ). Thus, dihydroartemisinic acid 
(2) can be obtained by reducing artemisinic acid (1) of the following formula 
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Thus the present invention is also directed to a method for producing artemisinin (6) from 
artemisinic acid (1) comprising the following steps: 
A) providing artemisinic acid (1) represented by the following formula 
0 
(1) 
B) reducing artemisinic acid (1) to dihydroartemisinic acid (2) of the following formula 
C) performing the following reactions 
0 
(2) 
i) photooxidation of dihydroartemisinic acid (2) with singlet oxygen in a 
continuous manner in a photochemical reactor, 
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ii) followed by an acid mediated cleavage and 
iii) subsequent oxidation with triplet oxygen 




In this embodiment the photooxidation is performed continuously in the photochemical 
reactor which is a component of the continuous flow reactor. The acid mediated cleavage 
[step ii)] as well as the oxidation with triplet oxygen [step iii)] can be performed in a batch 
process or in a semi-continuous manner or preferably also in a continuous manner. 
Further it is preferred that oxygen for the provision of singlet oxygen is provided to the 
continuous flow reactor above atmospheric pressure. Thus it is preferred if the 
photooxidation is performed under pressure and especially under oxygen pressure. It is 
more preferred if the oxidation with singlet oxygen and also the oxidation with triplet 
oxygen are performed under pressure and especially under oxygen pressure. It is most 
preferred if all three steps i) - iii) are performed under pressure and especially under 
oxygen pressure while the pressure can be different for each step or can be diminished 
during one step. 
In all methods according to the present invention is it preferred that the continuous flow 
reactor comprises a tube or tubing made of a fluorinated or perfluorinated alkylene 
polymer wherein the photooxidation of dihydroartemisinic acid takes place. It may also be 
preferred that the tubing is wrapped around a photochemical reactor containing the light 
source. 
The photooxidation of dihydroartemisinic acid (2) generally results in the intermediate 
products (3), (4) and (5) as also described in example 1. The main intermediate product 
is the hydroperoxide (3) which can be obtained by the process of the present invention in 
at least 75% yield, preferably in at least 80% yield and more preferably in at least 84% 
yield. In order to perform subsequent reactions such as the further preparation of 
artemisinin (6), preferably also in a continuous manner, it is not required to purify the 
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obtained hydroperoxide (3) or to remove the intermediate products (4) and (5) as shown in 
example 1. 
The hydroperoxide (3) of the following formula 
0 




the hydroperoxide (5) of the following formula 
OH 
0 
are formed as photooxidation products from the reaction of dihydroartemisinic acid (2) with 
singlet oxygen according to the present invention. 
As also described above, dihydroartemisinic acid (2) can be prepared from artemisinic acid 
(1 ). The starting material artemisinic acid (1) which is also known as arteannuic acid and 
which has the chemical name 2-[(1 R,4R,4aS,8aR)-4,7-dimethyl-1 ,2,3,4,4a,5,6,8a-
octahydronaphthalen-1-yl]prop-2-enoic acid can be obtained synthetically, by recombinant 
methods or can be isolated from the plant Artemisia annua. Since there is artemisinic 
acid and dihydroartemisinic acid contained in the plant Artemisia annua, an efficient 
method to convert artemisinic acid (1) and dihydroartemisinic acid (2) into the 
hydroperoxide (3) and subsequently to artemisinin (6) is desired. Thus the starting 
material artemisinic acid (1) or dihydroartemisinic acid (2) can be used as a plant extract in 
all reactor embodiments disclosed herein. Also, extraction protocols to remove artemisinic 
acid and dihydroartemisinic acid from artemisia annua have been published (Wallaart, T.E. 
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eta/., J. Nat. Prod. 1999, 62, 430-433), making use of the extraction of acidic compounds 
by aqueous base and the reextraction into an organic phase after acidification. 
An adapted procedure can be applied to such mother liquor remaining after removal of 
artemisinin from artemisia annua extracts. Thus, also the extract of artemisia annua after 
the removal of artemisinin can be readily used as starting material in all reactor 
embodiments disclosed herein. Therein the method of the present invention provides a 
possibility of sophistically using waste material of industrial scale. 
Also, in order to overcome drawbacks of photochemical reactions being performed in 
batch-like manner in the prior art, the inventors designed a continuous flow set-up which in 
contrast to said batch processes allows the production of large quantities of desired 
material by simply extending the run time rather than changing to larger reaction vessels. 
The continuous flow process of the present invention provides a highly complex natural 
product from a much less complex molecule that can be isolated in larger quantities or can 
be readily produced in yeast. The efficiency, simplicity and productivity of the approach 
will provide access to much needed medication against malaria. 
The methods of the present invention allow the synthesis of artemisinin, wherein 12.5 
mmol dihydroartemisinic acid are processed in a total residence time below 5 minutes 
through the continuous flow reactor in order to yield preferably at least 39% artemisinin of 
a purity above 95%. 
Excellent control over reaction parameters such as reaction time, temperature and mixing 
are hallmarks of flow chemistry and thus also provided by the method, the photochemical 
reactor and the continuous flow reactor according to the present invention. 
Photochemical transformations according to the present invention greatly benefit from the 
flow regime as the penetration depth of the light remains almost the same also during 
scale-up due to the dimensions of tubing that serves as reaction vessel. 
Thus, the significant disadvantages of the prior art were addressed by the present 
invention and were solved in a way that at least the photooxidation of dihydroartemisinic 
acid (2), but also subsequent steps starting from dihydroartemisinic acid (2) could be 
combined in a continuous flow system which can be easily controlled, easily scaled up, 
optimized to produce good yields and does not require the isolation and purification of any 
intermediates. Such advantages can not be provided by a batch-reaction of 
dihydroartemisinic acid (2) with singlet oxygen, and also optional subsequent continuous 
conversions to yield artemisinin (6) as described herein. 
In one embodiment of the invention the photochemical reactor comprises an assembly 
wherein the solution of dihydroartemisinic acid (2) and oxygen running through the tubing 
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which is wrapped around the filter, the light source and the immersion well of the 
photochemical reactor while this solution is irradiated by the light source. The outflow 
from the tubing can be processed in three different ways, namely in a batch process, or in 
a separate continuous flow process, or in a continued continuous flow process. In the 
following this setup of a photochemical continuous flow reactor is called the "immersion 
well assembly". 
In another preferred embodiment of this invention the photochemical reactor comprises an 
assembly wherein the solution of dihydroartemisinic acid (2) and oxygen is running 
through a tubing, wherein the photooxidation of dihydroartemisinic acid (2) takes place, 
and which is wrapped around a transparent body, which is placed inside a box, whereby 
the box also contains a light source. This box is like a "black box" and does not allow light 
to enter into or to leave the box. Thus the box is made of lightproof or opaque material 
and thus is impervious to light. The inner surfaces of the box are covered with light 
sources or with reflecting materials such as mirrors or aluminum foil. In another preferred 
embodiment the box is made of a reflective material such as aluminum or stainless steel. 
There are only two small holes in the box through which the tube for performing the 
photochemical reaction of dihydroartemisinic acid (2) with singlet oxygen enters and 
leaves the box. In the following, the described box setup of a photochemical continuous 
flow reactor is called the "box assembly". In another preferred embodiment the box 
assembly further comprises a cooling system wherein the photooxidation reaction occurs 
in a light proof box and the reactor can be cooled. In the following such a box setup of a 
photochemical continuous flow reactor is called the "cooled box assembly". 
Yet in another preferred embodiment of the present invention the reaction mixture may 
also flow over a broad transparent plate thereby transforming the volume of the liquid into 
a thin film which is irradiated by a light source through the transparent plate. In particular 
when irradiation occurs over a sufficient length of the formed film the residence time can 
significantly be decreased. The transparent plate can be fixed to a second plate leaving a 
gap between first and second plate for the liquid to flow. The second plate be made of a 
reflective material and further may be cooled. In the following such a setup of a 
photochemical continuous flow reactor is called the "falling film assembly". 
Still in another embodiment the reaction mixture max also flow through the tubing 7 in the 
form of a cylinder or a double-walled cylinder arranged around the light source and the 
solution or mixture of dihydroartemisinic acid flows through that cylinder or within the walls 
of the doubled-walled cylinder while being exposed to the light of the light source. One or 
more cooling cylinder might be present around the light source and/or around or within the 
cylinder or double-walled cylinder. In the following such a setup of a photochemical 
continuous flow reactor is called the "cylinder assembly". 
wo 2013/030247 PCT/EP2012/066800 
38 
General teachings 
The following general teachings are preferred embodiments which apply to all methods, 
photochemical reactors and continuous flow reactors disclosed herein if the teachings are 
not made in regard to a specific embodiment. 
Suitable light sources for all herein described assembled reactors comprise Hg lamps, 
neon lamps, light bulbs and light-emitting diodes (LED). 
Further, the photochemical reactor of the immersion well assembly, the box assembly and 
the cooled box assembly comprises a setup which consists of a tube made of a fluorinated 
or perfluorinated alkylene polymer, wherein the photooxidation of dihydroartemisinic acid 
(2) takes place. Such a polymer may be FEP (fluorinated ethylene propylene copolymer). 
However, also other polymers may be used for tubing such as ETFE (ethylene 
tetrafluoroethylene), ECTFE (ethylene chlorotrifluoroethylene), PFA 
(perflouroalkoxyalkane), PEl (polyetherimide), PPSF (polyphenylsulfone), PC 
(polycarbonate), PMMA (polymethyl methacrylate), PE (polyethylene) or PP 
(polypropylene). Any other materials that are transparent and resistant to the solvent and 
reagents such as silica tubing may also be used. 
In case of the box assembly and the cooled box assembly the tubing is wrapped around a 
transparent body, which is placed inside a box, whereby the inside of the box also contains 
at least one light source. 
In a preferred embodiment of the invention the light source of the box assembly and the 
cooled box assembly is a light-emitting diode, or even more preferred an assembly of light-
emitting diodes. The light-emitting diodes have a preferred light emitting wavelength of 
420nm and/or 660nm. Such an assembly of light-emitting diodes is preferably arranged in 
a plane module. As light source of the box assembly and the cooled box assembly there 
can be used only one of those modules. However, it is also possible to increase the 
number of modules or to increase the number of diodes and thereby the dimensions of the 
modules. The number of modules is not particularly limited as this number highly 
dependents on the dimensions of the reactor. In a preferred embodiment of the present 
invention the number of modules ranges from 1 to 100, more preferably from 1 to 50, and 
is most preferably 1 . 
In a more preferred embodiment of the invention the setup of light-emitting diodes is a 
plane module having an emission-surface within 0.5 x 0.5 cm2 to 20 x 20 cm2, or even 
more preferred of at least 2.5 x 2.5 cm2. 
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In another preferred embodiment of the invention the setup of the arranged LED's are 
within a plane module having an emission-surface within 25 x 120 cm2 to 50 x 50 cm2, or 
even more preferred of at least 44 x 88 cm2. The emission angle of the diodes ranges 
from goo to 150°, and is preferably 120°. 
Residence times for irradiation depend on the amount of feed being irradiated and the 
concentration of reactants as well as of the photosensitizer. Preferred residence times for 
the performance of the photooxidation in all reactor assemblies according to the present 
invention range from 5 seconds to 5 hours, preferably from 30 seconds to 30 minutes, 
more preferably 1 minute to 1 0 minutes and most preferably from 2 minutes to 5 minutes. 
One specifically preferred irradiation occurs for 2 minutes at an electrical output of 72 W. 
The use of LEOs is particularly preferred for the present invention as the LEOs, preferably 
arranged in a module do not emit UV-radiation which would lead to undesired side 
reactions. In addition specific UV-Iight filters are not necessary. 
Within the box assembly and the cooled box assembly containing the light source and the 
tubing wrapped around a transparent body, more than one module of light emitting diodes 
may be arranged around the wrapped tubing, containing the dihydroartemisinic acid (2) 
and the oxygen for the photooxidation reaction. In a preferred embodiment the box can 
also be any suitable containment being water proof and capable of keeping a certain 
amount of liquid such as a container, a bucket, a tray, a vessel or a bowl, preferably 
equipped with reflectors or with a reflecting surface on the inner wall. 
In a more preferred embodiment of the invention the inner walls of the box or containment 
containing the tubing and the light source, may consist of or have a light reflecting surface 
and/or the box containing the tubing and the light source may comprise reflectors, having a 
light reflecting surface, wherein the reflectors are arranged around the tubing and the light 
source. 
In a preferred embodiment of the invention the light reflecting surface and/or the reflectors 
lead to a specular reflection of the light of the light source within the box. 
The light reflecting surface and/or the reflectors comprise or contain an assembly or a 
material which belong to the group of: astro-foil, polished anodized aluminum, Mylar, 
metallized biaxially-oriented polyethylene terephthalate, aluminum foil, can lids, tinplate, 
acrylic mirror, glass mirror, metall mirror, ceramic mirror, glass-ceramic mirror, mirrors 
made out of Borofloat, Pyrex, Cervit, Sital, Zerodur, wherein the mirror is defined as a 
suitable substrate which is coated with a light reflective material. The substrate is 
preferably glass, ceramic or glass-ceramic, due to its transparency, ease of fabrication, 
rigidity, hardness, and ability to take a smooth finish. The reflective coating is typically 
applied to the back surface of the substrate, so that the reflecting side of the coating is 
wo 2013/030247 PCT/EP2012/066800 
40 
protected from corrosion and accidental damage by the glass on one side and the coating 
itself and optional paint for further protection on the other. The reflective coating is made 
out of silver, aluminium or other reflecting metals. On the other hand the substrate may 
be made out of polished metal itself. For the cooled box assembly the main body 
containment is preferably made of aluminum or stainless steel. However, also other 
materials are suitable such as chromium, molybdenum, silver, gold, lead or alloys thereof. 
In other words the light reflecting surface and/or the reflector may be made out of a light 
reflecting material which has a light reflectivity of at least >70 %, or more preferably >90%, 
wherein the reflected light spectra comprises the wavelengths needed to perform the 
photooxidation reaction of dihydroartemisinic acid (2). In a preferred embodiment of the 
invention the reflected spectra in the box assembly contains the wavelengths of 420nm 
and/or 660nm. 
According to the invention in all embodiments of reactors the use of photosensitizers is 
essential. All photosensitizer capable of promoting the generation of singlet oxygen could 
be used such as fullerenes, several transition metal complexes and semiconductors like 
titanium oxide and zinc oxide. Therefore, at least one photosensitizer is preferably added 
to the solution of dihydroartemisinic acid, which can be excited easily by light and transfers 
its energy to the dissolved oxygen. Many different known photosensitizers are suitable for 
this application; preferably the photosensitizers have at least one of the following features: 
- a high extinction coefficient, so that a low concentration of photosensitizer can be used, 
making the process more cost-effective; 
- a high quantum yield for singlet oxygen production, which means that a large amount of 
singlet oxygen can be produced per number of photons, making the process more energy 
efficient 
- inertness, so that no undesired side-reactions e.g. with solvent or added reagents occurs; 
-high photostability of the sensitizer, resulting in no decrease in yield over time; 
- high target-selectivity in that the exited sensitizer transfers its energy selectively onto 
triplet oxygen and not onto other added reagents preventing the formation of side 
products; 
-absorption at long wavelength in the visible range as these photons possess less energy, 
making the process more energy efficient; 
- insensitivity towards acid facilitating an initial addition of the acid necessary to induce 
Hock cleavage. 
Particularly suitable photosensitizer for use in a process according to the present invention 
are, for example: tetraphenylporphyrin, 5,1 0, 15,20-tetrakis(pentafluorophenyl)porphyrin, 
tris(2,2'-bipyridyl)ruthenium(ll), pheophytin a, pheophorbide a, 2,3,7,8-dibenzopyrene-1 ,6-
quinone and metal-phthalocyanines. 
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However, also other photosensitizers are suitable for the photooxidation reaction of the 
present invention. Such photosensitizers can be zinc tetraphenylporphyrin or 9,10-
dicyanoanthracene. In some embodiments the preferred photosensitizer is 9,10-
dicyanoanthracene. In a preferred embodiment of the present invention the concentration 
of the photosensitizer ranges from 0.025 mM to 10 mM, more preferably from 0.05 to 9.0 
mM, and most preferably from 0.75 to 2.5 mM. 
For tetraphenylporphyrin, 9,1 0-dicyanoanthracene and zinc tetraphenylporphyrin is was 
found that good to excellent conversions of DHAA (2) to the hydroperoxide (3) in toluene 
can be achieved at already very low concentrations (Figure 1 OB). Specifically, for 
tetraphenylporphyrin it is was found that with relatively low concentrations of TPP (0.05 
mol%) a high conversion of dihydroartemisinic acid can be achieved. Further increase in 
the concentration slightly improves the yield. 
In a specifically preferred embodiment of the present invention the concentration of 
tetraphenylporphyrin is 0.75 mM and of 9,1 0-dicyanoanthracene is 2.5 mM each in 
toluene. 
Photosensitizers can either be solubilized in the solvent (homogeneous system), 
immobilized on a solid support or any solid capable of promoting the generation of singlet 
oxygen may be used. 
In general a photosensitizer as described herein is mixed with the reaction materials 
comprising dihydroartemisinic acid (2) and oxygen, and in a preferred embodiment the 
mixture is led through the transparent tube through the continuous flow reactor. 
The electrical output of the light emitting diode or light emitting diode assembly is 
preferably between 60 and 100 W, and the light output of the light emitting diode or light 
emitting diode assembly is preferably between 5-50 W. In another preferred embodiment 
the optical output of the high energy LED module is up to 400 W and preferably ranges 
from 200 to 350 W, and is most preferably 280 W. 
In another embodiment of the invention a Pyrex filter may be arranged between the light 
source and the tubing to absorb wavelengths below 300 nm, to prevent degradation of the 
tubing, and to avoid any undesired side reactions involving short wavelength light, wherein 
the Pyrex filter has a preferred thickness from 0.5 to 10 mm. 
The continuous flow reactor of the box assembly comprises a tube made of a fluorinated 
or perfluorinated alkylene polymer having a preferred outer diameter within 0.0625 and 
0.25 inch, and a preferred inner diameter within 0.03 and 0.12 inch. The corresponding 
tube volume lies preferably within the range of 3 to 30 mi. 
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Alike the "immersion well assembly" shown in Figure 1 and 4, the "box assembly" as 
described above as well as the "cooled box assembly" as shown in Figure 8, 9A and 98 
use a solution of dihydroartemisinic acid (2), with a preferred concentration of about 0.2 -
1.0 mol/1 in a proper solvent, which is led through the reactor by a simple HPLC pump, 
which has a preferred flow rate within 1 ml/min to 20 ml/min. Oxygen gas is added to this 
solution preferably by aT-type mixer before being led through the reactor. 
According to the present invention the continuous conversion of dihydroartemisinic acid (2) 
requires the presence of oxygen gas in the reaction mixture for the photooxidation 
reaction. Further, also the Hock cleavage for the production of artemisinin (6) requires 
oxygen in the reaction mixture. This oxygen gas is preferably dissolved in high 
concentration, more preferably in the form of a saturated solution in the reaction medium. 
The method of the present invention comprises the provision of high oxygen levels within 
the reaction mixture by providing a set-up which allows a steady oxygen flow into the 
reaction mixture in order to generate high oxygen concentrations, preferably upon 
increased pressure within the reactor such as the tubing system. A steady flow can be 
provided according to the present invention by an oxygen tank being connected to a 
m1x1ng device where the reaction medium containing photosensitizer and 
dihydroartemisinic acid (2) is brought in contact with oxygen. In a preferred embodiment 
the oxygen tank is further equipped with a manometer, a flow control and a check valve. 
According to the present invention oxygen can also be provided by a gas mixture 
containing oxygen as long as the other gas mixture components do not significantly 
interfere with the reaction or reagents. Suitable oxygen containing gas mixtures are air or 
synthetic air. Also, a simple mixture of oxygen with an inert gas such as nitrogen or noble 
gases may be suitable for the present invention. Oxygen or an oxygen containing mixture 
is preferably provided under increased pressure to the reaction mixture. Elevated 
pressure increases solubility of oxygen gas in the solvent and thus facilitates short 
residence times. The pressure for a suitable oxygen flow may range from atmospheric 
pressure to 50 bar, preferably from 5 bar to 20, more preferably from 7.5 bar to 15 bar and 
most preferably from 10 bar to 12 bar. 
A steady oxygen flow is particularly preferred for the present invention as a continuous 
process requires the continuous provision of a reactant. Suitable flow rates according to 
the present invention range from 1 to 15 ml/min, preferably, 3 to 10 ml/min and most 
preferably from 5 to 7.5 ml/min. 
Also, to further allow high oxygen levels within the reaction mixture back pressure 
regulators may be assembled in a reactor according to the present invention. Such a 
back pressure regulator allows keeping the pressure within the system, i.e. the tubing or 
any other reactor part, at an elevated pressure level, preferably ranging from 1.5 bar to 15 
bar, more preferably from 2.2 bar to 10 bar and most preferably from 5 bar to 8 bar. 
It is also part of the present invention that upon consumption of oxygen out of the reaction 
mixture a pressure gradient may occur over the length of the reactor. In another 
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embodiment of the present invention several gas inlets may be incorporated in the reactor 
design allowing the installation of an adjustable pressure gradient within the reaction 
mixture. 
As also stated above, the pressure drop over the length of the tubing 7 depends on 
various parameters and can be calculated in the laminar flow regime by the following 
11p = 8J1Lq 
formula Trr 4 , whereby 1J is the dynamic viscosity of the solvent, L is the length of the 
tubing, q the volumetric flow rate and rthe inner radius of the tube. 
Taking into account the roughness of the tube the actual pressure drop is higher. With a 
typical reactor setup (as given in example 12) and a back pressure regulator of 8 bar being 
attached to the exit of the reactor, a system pressure of about 10-12 bar after the pumping 
unit and before entering the photochemical reactor at the is found. The pressure drop of 
the whole reactor system is about 2-4 bar. The pressure of the regulator of the oxygen 
tank can be set preferably to 15 bar, further allowing adjustment of the flow rate with a gas 
flow controller. Due to the high oxygen pressure of 10-12 bar in the photochemical reactor 
of the continuous flow reactor, a higher oxygen solubility compared to atmospheric 
pressure is achieved. The pressure of> 8 bar after the photochemical reactor is beneficial 
for the triplet oxidation occurring as well. 
Also, oxygen availability in the system may be further increased by performing the reaction 
in perfluorinated solvents, such as hexafluorobenzene, or solvents with fluorinated 
moieties such as benzotrifluoride or bis(trifluoromethyl)benzene, which are characterized 
by a higher oxygen solubility. These additives may also be employed together with 
nonfluorinated solvents. 
Because of the scale to t 4 the pressure drop can be reduced by a factor of 16 by doubling 
the tube diameter. Given a dynamic viscosity of 0.590 cP for toluene, the following 
pressure drops can be calculated: 
inner diameter tubing volume per pressure drop at q = 10 ml/min 
meter for volume of 100 ml 
0.030" (1/16" outer diameter tube) 0.44 ml 29 bar (227m tubing) 
0.75 mm 
0.062" (1/8" outer diameter tube) 1.89 ml 0.4 bar (52.9 m tubing) 
1.55 mm 
0.156" (1/4"outer diameter tube) 12.6 ml 0.001 bar (7.94 m tubing) 
4.0mm 
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A steady oxygen flow and associated with a high oxygen level in the reaction mixture is 
facilitated on the one hand by incorporation of mixing devices and by a reactor design 
capable of withstanding high pressure. Therein, the reactor design can be adjusted to 
uphold pressure in the entire system over at least one reaction component, preferably 
more than one reaction component until the reaction mixture exits for further reaction 
steps. 
In a even more preferred embodiment of the invention the concentration of 
dihydroartemisinic acid (2) within the box assembly is 0.5 mol/1, wherein the flow rate in an 
explicit run of the reactor may lead to the corresponding conversion-, selectivity- and yield-
values for the production of artemisinin (6), as shown in Table 1: 
Table 1 
flow-rate of solution yield 
of starting material flow-rate-1 conversion hydroperoxide selectivity 
(3) 
ml/min mmol/min min mmor1 mmol/min 
0 0 0 0,0% 0,00 0,0% 
5 2,5 0,4 51,4% 1,29 36,7% 71,3% 
2,5 1,25 0,8 82,9% 1,04 59,2% 71,4% 
1,75 0,875 1,143 90,3% 0,79 66,7% 73,9% 
1,25 0,625 1,6 99,3% 0,62 72,7% 73,2% 
In contrast to the prior art the present invention provides a continuous photooxidation of 
dihydroartemisinic acid (2) enabling a steady processing which further facilitates a large 
conversion without the necessity of upscaling and which is not possible by a batch reactor 
design. Also, the present invention provides a process wherein dihydroartemisinic acid 
(2) is continuously converted by use of a mixture which is provided by the mixing gaseous 
oxygen preferably under pressure into the dihydroartemisinic acid solution for the 
photooxidation reaction requiring a specific reactor design for pressurized solutions with a 
potentially highly flammable gas. 
Further, in another embodiment of the present invention the reaction sequence does not 
include a separation and/or isolation step during the conversion of dihydroartemisinic acid 
(2) to artemisinin (6). Also, depending on the reactor design it is possible to run the 
production of artemisinin according to the present invention in a semi-continuous manner. 
For example, in a semi-continuous reactor design the reaction solution and oxygen are 
delivered into the irradiation reactor compartment and are removed after a certain period 
of irradiation, e.g. by pumping the solution out from the reactor or by delivering new 
reagents. Such a semi-continuous reaction process can be performed periodically. 
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Preferably, the steps of conversion of dihydroartemisinic acid (2) with singlet oxygen and 
subsequently the reaction of the reaction product(s) of the aforementioned reaction step 
with oxygen in the presence of trifluoroacetic acid are conducted in a continuous manner. 
In case of the immersion well assembly, the box assembly and the cooled box assembly 
as well as in the falling film assembly and the cylinder assembly the hydroperoxide (3) 
contained in the outflow of the reactor compartment of the photochemical reactor has to 
undergo an acid mediated cleavage of the hydroperoxide bond followed by subsequent 
oxidation preferably with oxygen (more specific with triplet oxygen) in order to obtain 
artemisinin (6). 
Thus as outlined above, the hydroperoxide (3) is produced in the photochemical reactor of 
the present invention in a continuous flow process, while the next reactions can be 
performed by continuing said continuous flow process, starting a new continuous flow 
process or switching to a batch process. 
In case of switching to a batch process, it is still not necessary to purify the hydroperoxide 
(3) or to remove the intermediate products (4) and (5). The obtained hydroperoxide (3) is 
simply collected in a batch reactor like a flask, is flushed with oxygen or an oxygen 
containing gas such as air, and treated with an acid such as TFA in order to obtain 
artemisinin (6). This method combining continuous flow through the photochemical 
reactor with subsequent batch process is described in example 2. 
The second possibility of starting a new continuous flow process includes collecting the 
reaction solution coming out of the the photochemical reactor of the continuous flow 
reactor which contains the hydroperoxide (3) and the intermediate products (4) and (5). 
No purification step or removal of the intermediate products (4) and (5) is required in order 
to perform the next reactions. The collected reaction solution may be concentrated or 
diluted and is fed into a second component of the continuous flow reactor together with 
oxygen or an oxygen containing gas such as air and an acid such as TFA in order to 
produce artemisinin (6), while this solution is running through that second continuous flow 
reactor. This method combining continuous flow through the photochemical reactor with 
subsequent continuous flow through the second continuous flow reactor is described in 
example 3. This method might be preferred in a case where more material could be 
processed through the second component of the continuous flow reactor than through the 
photochemical reactor so that probably the reaction solutions of two or more 
photochemical reactors are collected and then processed through one single second 
component of the continuous flow reactor. 
The most preferred method is to continue the continuous flow process which is most 
preferred if photochemical reactor and subsequent continuous flow reactor have a similar 
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capacity. In that method the reaction solution coming out of the photochemical reactor is 
directly forwarded to and/or fed into the subsequent continuous flow reactor components 
without first collecting said reaction solution. The acid is in one embodiment preferably 
added to the reaction solution coming out of the photochemical reactor and oxygen or an 
oxygen containing gas such as air is also fed into this reaction solution so that the 
hydroperoxide (3) in the reaction solution fed into the subsequent continuous flow reactor 
components is cleaved by the acid and oxidized by the triplet oxygen to the final product 
artemisinin (6). This most preferred method using one single continuous flow process 
from the production of artemisinin (6) from dihydroartemisinic acid (2) is described in 
example 4. 
The photooxidation of dihydroartemisinic acid (2) was explored in a home-built continuous 
flow reactor as shown in Figures 1 and 4, comprising a photochemical reactor consisting of 
fluorinated ethylene propylene (FEP) tubing wrapped around a Schenk photochemical 
reactor containing a 450 W medium pressure mercury lamp that was cooled to 25°C. 
Such a reaction set-up refers to an immersion well assembly. Generally, preferred are 
photochemical reactors having a volume between 10 ml and 30 mi. A solution of 
dihydroartemisinic acid (2) in an organic solvent was added via a HPLC pump and oxygen 
was delivered via a mass flow controller connected to a gas cylinder. The solution of (2) 
and the oxygen gas were mixed using a ethylene tetrafluoroethylene (ETFE) T-mixer. 
Tetraphenylporphyrin (TPP) was used as photosensitizer due to its high quantum yield and 
high stability against photo-bleaching. Alternatively, rose Bengal (R.B.) and methylene 
blue (M.B.) can also be used as photosensitizer. Any other photosensitizer capable of 
promoting the generation of singlet oxygen could be used, for example: 5,1 0,15,20-
tetrakis(pentafluorophenyl)porphyrin, tris(2,2'-bipyridyl)ruthenium(ll), pheophytin a, 
pheophorbide a, 2,3,7,8-dibenzopyrene-1 ,6-quinone and metal-phthalocyanines. 
In the case of the immersion well assembly, the box assembly and the cooled box 
assembly FEP or fluorinated ethylene propylene refers to a copolymer of 
hexafluoropropylene and tetrafluoroethylene. Other suitable fluorinated polymers are 
PTFE (polytetrafluoroethylene) and fluorinated ethylene propylene copolymers from 
DuPont sold under the brandname Teflon® FEP. 
In the case of the immersion well assembly and the box assembly, the inventive method is 
preferably carried out at a temperature of 25°C. In general, a preferred temperature 
range is between -50 and 60°C, more preferred between 20 and 40°C. Generally, the 
inventive system can be well thermosetted resulting thereby in reliable and reproducible 
operation. Also, the inventive method can be cooled down to any desirable temperature 
only limited to physical barriers such freezing of the solvent or precipitation of one reactant 
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from the reaction mixture. However, the inventive method can also be heated up to a 
temperature at which a solvent would start to boil and incur damages to the reactor. 
In some embodiments such as the cooled box assembly, the cylinder assembly or the 
falling film assembly embodiment it is preferred that the temperature for the photooxidation 
reaction ranges from room temperature down to -30°C, more preferably from 1 0 oc to -25 
oc, even more preferably from 0 octo -20 oc, yet even more preferably from -10 octo -20 
oc, and most preferably from -15 octo -18 °C. In a preferred embodiment the temperature 
for the photooxidation reaction is -20 oc 
It was found that the selectivity of the reaction can be improved in terms of a low amount 
of byproducts when the photooxidation reaction is performed at low temperatures, such as 
below 0 oc as defined above. In a preferred embodiment the photooxidation reaction is 
performed at -18 °C. It was found that the conversion of the starting material DHAA is 
nearly complete in a temperature range from -20 oc to 80 °C. It was further found that 
lower temperature beneficially influences a shifting of the ratio of the different peroxides 
towards the preferred hydroperoxide (3) in comparison to the byproducts (4) and (5). 
Specifically, the reaction temperature has a pronounced effect and at low temperature of 
e.g. -18 oc the amount of side products can be decreased to 5%. At this temperature, a 
maximum selectivity of 82% for the desired peroxide is obtained. It is therefore worthy to 
cool the reactor for the photooxidation step in order to obtain a higher yield of artemisinin 
(6) and less side products granting the benefit of simplifying later purification. 
Also, it was found that an efficient cooling system such as introduced by the cooled box 
assembly further provides the possibility of increasing the energy level of the induced 
radiation during the photooxidation reaction since an energy transfer of radiation heat to 
the cooling liquid can occur. Therefore, running the continuous flow reaction of 
photooxidation at decreased temperatures high energy radiation can be applied in order to 
efficiently convert DHAA (2) to the preferred hydroperoxide (3). Further, by increasing the 
energy input on the photooxidation reaction the production capacity can approximately be 
increased by the factor the energy input is increased. Thus, increasing the energy input 
by a factor 5, the product capacity may preferably be increased by a factor 5. 
Since oxygen gas can result in severe fires a non-flammable, typically halogenated solvent 
is required. On large scale, halogenated solvents other than dichloromethane are 
considered too toxic so that dichloromethane is the preferred solvent for large scale 
production of artemisinin (6). But also other solvents have been found of being particular 
suitable for the production of artemisinin (6). Among those other suitable solvents, 
besides dichloromethane, there are fluorinated and perfluorinated C4-C6 hydrocarbon 
solvents, fluorinated and perfluorinated aromatic solvents such as 1 ,3-
bis(trifluoromethyl)benzene, hexafluorobenzene and benzotrifluoride, aromatic solvents 
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such as benzene, toluene, mesitylene and xylenes as well as cyclohydrocarbon solvents 
such as cyclobutane, cyclopentane, cyclohexane and cycloheptane. Fluorinated solvents 
were found to exhibit high oxygen solubility and long lifetime of singlet oxygen, which is 
beneficial for the first photooxidation step. For the acid catalyzed reaction fluorinated 
aromatic compounds perform well concerning artemisinin yield and prevention of 
byproducts. Further preferred for the synthesis of artemisinin according to the present 
invention are 1 ,3-bis(trifluoromethyl)benzene, hexafluorobenzene and benzotrifluoride, 
toluene and cyclohexane, and most preferred is toluene. Under preferred conditions, 1.50 
mmol of intermediate (3) were produced per minute when a 10 ml to 60 ml reactor and 
preferably a 20 mL reactor was fed with 2.5 ml/min of the solution of dihydroartemisinic 
acid (2) in dichloromethane and oxygen was fed at a flow rate of 5 ml/min. At 91% 
conversion and a yield of 75% for this step this process was better or at least as good as 
any process ever described for this transformation. 
Protonation of the peroxide (3) is required to induce cleavage and rearrangement of the 
cyclic structure. The intermediate product evolved from the protonation of the 
endoperoxide oxygen atom of compound (3) undergoes undesired reactions which in the 
state of the art have been suppressed by the conversion of the carboxylic acid into an 
ester or a mixed anhydride. Such a transformation requires additional steps and the use 
of the carboxylic acid reduces considerably the formation of the 6-membered lactone 
product. The inventive method disclosed herein does not require the protection of the 
carboxylic acid group as an ester or mixed anhydride. 
For efficiently performing the method of the present invention different Bmnsted and Lewis 
acids were tested in various solvents in order to find the most efficient path for converting 
the peroxide obtained after the singlet oxygen reaction into the intermediate which is 
reacted with triplet oxygen to obtain artemisinin (6). As result from this screening, acids 
can either be used in a homogeneous fashion or in an immobilized form as an acidic ion 
exchange resin. The following Bmnsted and Lewis acids were tested: camphorsulfonic 
acid, copper(ll) trifluoromethanesulfonate, DOWEX®, p-toluenesulfonic acid, trifluoroacetic 
acid amberlite IR 120 ion exchange resin, acetic acid, sulfuric acid and cone. hydrochloric 
acid. Other suitable Bmnsted or Lewis acids having similar pKa could be used. There 
are no special requirements for the acid. Trifluoroacetic acid (TFA) performed so far best 
as acid to induce the Hock cleavage, but other acids with similar pKa could also be 
feasible. Moreover, addition of small amounts of water to the TFA solution did not 
deteriorate conversion and/or selectivity. Therefore, it is preferred for the method of the 
present invention that trifluoroacetic acid is used for the acid mediated cleavage. 
Additionally, not only heterogeneous acids for the Hock cleavage can be immobilized on 
the surface of the compartments material, but also heterogeneous photosensitizers 
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resulting in a high contact area significantly promoting the various reactions within the 
reactor of the present invention. 
It is essential to point out that a Bmnsted acid or a Lewis acid needs to be added to 
perform the Hock cleavage. This addition could be done directly at the beginning or just 
after the completion of the reaction with singlet oxygen. The addition of the acid after the 
photooxidation reaction is preferred in case an acid-sensitive photosensitizer is employed, 
so that preferably the acid is added to the reaction solution leaving the photochemical 
reactor. For example, treatment of the crude tertiary allylic hydroperoxide (3) obtained 
from the photochemical reactor with 0.5 eq. of TFA at ooc while bubbling oxygen (pure 
oxygen or air) gave, after purification by chromatography, artemisinin (6) in 50% yield. 
In an effort to minimize manipulations of the reaction mixture and move to a fully 
continuous process, the Hock cleavage step with the action of acid and the addition of 
oxygen were performed in one continuous flow set-up. Best results were obtained in a, 
for instance, 42 ml reactor at a flow rate of, for instance, 2.5 ml/min of the crude tertiary 
allylic hydroperoxide (3) in dichloromethane, a flow rate of 5.0 ml/min of oxygen and a 
flow rate of 0.5 ml/min of TFA in dichloromethane. The first portion of the reactor (32 ml) 
was preferably maintained at room temperature and the last portion (1 0 ml) was 
preferably heated at 60oc to push the reaction to completion. The ensuing triplet oxygen 
oxidation produced desired artemisinin (6) and five member lactone byproduct in a ratio of 
5.3:1.0 in favor of (6). Following purification by chromatography yielded 46% of (6) in this 
sequential continuous flow multistep reaction from dihydroartesiminic acid (2). 
Further, it was found that the temperature of the reaction mixture after the photooxidation 
reaction for the acid-catalyzed reaction cascade has significant impact on the conversion 
of the hydroperoxide (3) into the desired product artemisinin (6). It was found that 
decreased temperatures ranging from 0 octo -15 oc only provide high yield of the desired 
reaction product artemisinin (6) if the reaction duration is unfavorably extended. However, 
it was surprisingly found that high yields of artemisinin (6) can be derived preferably in a 
temperature range of 10 oc to 50 oc, more preferably in a range of 15 oc to 30 oc, and 
most preferably at 25 oc (Figure 10 A). It was further found that increasing the 
temperature over the preferred temperature range results in a more pronounced formation 
of byproducts while the artemisinin yield decreases. 
Moreover it was found that solvents with a lower dipole moment resulted in better 
selectivity so that the acid and especially TFA was dissolved in toluene, benzene, 
cyclohexane, xylene or dioxane. 
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The final synthetic transformation of the intermediate compound obtained after acid 
cleavage to artemisinin (6) requires an oxidation with triplet oxygen that is followed by a 
cascade of reactions that produce two rings, including the peroxide framework of 
artemisinin (6). According to one embodiment of the present invention, the Hock 
cleavage step with the action of acid and the addition of oxygen were performed in one 
continuous flow set-up as shown in Fig. 2. 
In comparison to batch processes a continuous process and reactor design as described 
herein allow the use of smaller dimensions of the various reactor parts and compartments. 
However, it is still possible to undergo an up-scaling with the reactor design of the present 
invention by for example extending the length of the tubing/reaction components. 
Adequate geometries can be applied to the tubing or other components with small 
thickness or dimensions. Such adjusting of dimension can also be applied to a falling film 
assembly, e.g. to the different plates and the gap between these plates allowing a liquid 
film with different thickness to flow in the centre. 
The possibility of applying small dimensions and/or diameters for the components of the 
continuous flow reactor of the present invention where the reactions occur is 
advantageous over batch reactor design. In that, it is possible to adjust a design with a 
high specific surface area. This is for example beneficial for a fast mass transport of 
oxygen from the gas phase into the solution. An efficient irradiation can be achieved as 
the intensity of light decreases with increasing distance from the light source. Therefore, 
big vessels generally used in batch reactor design are difficult to irradiate. Structures with 
thin diameter on the other hand can easily be irradiated with high intensity and the reaction 
accelerated significantly. 
Also as part of the reactor design, various reactor parts and components may be used that 
work on the basis of mechanic principles. For example, mixing pieces, pressure gauges, 
flow meters, mixing devices and back pressure valves may be designed to work in a 
classic fashion without the necessity of electrical power. However, various reactor parts 
and components such as mixing pieces, pressure gauges, flow meters, mixing devices 
and back pressure valves as well as the lights sources, cooling systems and pumps may 
also be designed to run electrically and can be controlled in a remote fashion from a 
computational unit if desired. 
These various reactor parts and components all add up to the continuous flow reactor of 
the present invention. Preferably this continuous flow reactor at least comprises a 
photochemical reactor for the production of artemisinin from dihydroartemisinic acid 
comprising 
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a light source, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and 
having an inlet for the mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end. 
The continuous flow reactor according to the present invention may further comprise an 
oxygen source capable of providing oxygen above atmospheric pressure. In a preferred 
embodiment of the present invention this oxygen source is an oxygen tank with a 
manometer, a flow control and/or a check valve. In the photochemical reactor according 
to the present invention the reactor compartment may be tubing. Also in the 
photochemical reactor according to the present invention the mixing device is a T-mixer 
valve. 
In a preferred embodiment of the present invention the photochemical reactor may 
comprise 
a box which is impervious to light with light reflecting inner walls and one opening 
through which the tubing enters the box and another opening through which the tubing 
leaves the box and 
multiple loops of the tubing arranged in the inside of the box, wherein the tubing 
has an inlet for a mixture of dihydroartemisinic acid and oxygen on its one end before 
entering the box and an outlet for the reacted products on the opposite end after leaving 
the box, and the continuous flow reactor of the present invention may optionally also 
comprise 
a cooling liquid and a chiller, as well as 
a back pressure regulator, in addition to the afore-mentioned photochemical 
reactor. 
However, it may also be that the photochemical reactor according to the present invention 
only comprises 
a light source, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment being at least partially irradiated by the light source and having 
an inlet for the mixture of dihydroartemisinic acid and oxygen on its one end and an outlet 
for the reacted products on the opposite end. 
In such a case it may also be that the continuous flow reactor of the present invention may 
further comprise an oxygen source capable of providing oxygen above atmospheric 
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pressure. In a preferred embodiment of the present invention this oxygen source is an 
oxygen tank with a manometer, a flow control and/or a check valve.. The continuous flow 
reactor of the present invention may further comprise: 
a box which is impervious to light with light reflecting inner walls and one opening 
through which the tubing enters the box and another opening through which the 
tubing leaves the box and 
multiple loops of the tubing arranged in the inside of the box, wherein the tubing has 
an inlet for a mixture of dihydroartemisinic acid and oxygen on its one end before 
entering the box and an outlet for the reacted products on the opposite end after 
leaving the box, and may optionally also comprise 
a cooling liquid and a chiller, 
a feed for an acidic solution, 
at least one reactor for producing or completing the synthesis of artemisinin, 
connected downstream to the photochemical reactor, 
a collection flask for collecting the artemisinin-containing solution from at least 
one reactor, 
a second reactor downstream to the first reactor or 
a second reactor downstream to the first reactor and 
a third reactor downstream to the second reactor, 
a back-pressure regulator downstream to the first reactor or the second reactor 
or the third reactor, 
a pump for the feed of the photochemical reactor containing at least 
dihydroartemisinic acid, solvent and photosensitizer, optionally further 
comprising acid, 
a check-valve between a first pump and the first mixer, 
a mass flow controller disposed between the oxygen tank and the first mixer for 
controlling the oxygen flow rate, 
a check valve between the mass flow controller and the first mixer, 
a second mixer connected to the outlet of the tubing of the photochemical 
reactor and to the acid feed and 
a second pump for pumping the acidic solution to the second mixer. 
Immersion well assembly 
In the case of the immersion well assembly, the invention refers to a photochemical 
reactor for the production of artemisinin (6) from dihydroartemisinic acid (2) comprising or 
consisting of 
a light source 11, 
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an immersion well 9 surrounding the light source 11, 
a filter 8 surrounding the light source 11 and 
PCT/EP2012/066800 
multiple loops of a tubing 7 wrapped tightly around the filter 8, the tubing 7 
having an inlet for a mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end. 
The immersion well 9 surrounding the light source 11 preferably in a cylinder-like shape 
and the filter 8 surrounding also the light source 11 preferably in a cylinder-like shape 
while the filter 8 could be inside the immersion well 9 or the immersion well 9 could be 
inside the filter 8. If the filter 8 is inside the immersion well 9 surrounding the light source 
11, the tubing is directly wrapped around the immersion well 9 and indirectly also wrapped 
around the filter 8 and the light source 11. If the immersion well 9 is inside the filter 8 
surrounding the light source 11, the tubing is directly wrapped around the filter 8 and 
indirectly also wrapped around the immersion well 9 and the light source 11. However it 
is preferred that the light source 11 is directly surrounded by the immersion well 9 and the 
immersion well 9 is again surrounded by the filter 8 and the filter 8 is again surrounded by 
the tubing 7. 
Tightly wrapped, as used herein, means that the tubing is wrapped around the filter in such 
a way that it keeps tight to the underlying filter and is not liable to slide down or to be 
shifted involuntarily or by applying flow pressure and/or temperature to the device. On the 
other hand it isn't wrapped that tightly that the tubing material gets overstretched and could 
be easily damaged by physicochemical stress or use. The main difference between the 
photochemical reactor used within the present invention and any common photochemical 
reactor such as the Scheck photochemical reactor is that the reactor vessel which usually 
surrounds the immersion well is replaced by the tubing which is wrapped around the filter 
and the immersion well. 
In the case of the immersion well assembly and the box assembly a Pyrex filter is 
preferred as filter. Preferably, it has an inner diameter of 4.85 em and a wall thickness of 
0.28 em. The diameter of the filter is related to the diameter of the immersion well. The 
filter could also be placed inside the immersion well, just around the lamp. In that case 
the diameter of the filter is smaller but the thickness is the same. 
For the tubing of the photoreactor FEP (fluorinated ethylene polymer) is preferred as 
material. A preferred FEP tubing is from IDEX Health & Science, FEP 1520, natural color, 
outside diameter (OD) 1/16 in and inside diameter (ID) 0.030 in). Another preferred 
tubing may have an outside diameter (OD) 1/8 in. In general, the internal diameter (ID) can 
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be from 0.003 in to 0.120 in. FEP tubing having the internal diameter of 0.003 in, 0.004 
in, 0.008 in, 0.010 in, 0.020 in, 0.030 in, 0.062 in, 0.125 in, 0.156 in, 0.250 in, 0.5 mm, 1 
mm, 2 mm and 3 mm are easily commercially available. In general, the outer diameter 
(OD) can be from 1/32 in to 4 mm. FEP tubing having the outer diameter of 1/32 in, 1/16 
in, 1/8 in, 3/16 in, 1/4 in, 5/16 in, 1 mm, 2 mm, 3 mm and 4 mm are easily commercially 
available. Alternatively, fluorinated or perfluorinated alkylene polymer or fluorinated 
ethylene propylene can be used FEP was preferably selected for the tubing due to its 
high transmittance and stability in the UV-vis light range, its flexibility and its high chemical 
resistance. Any polymer having these properties could be used instead of FEP. 
In the case of the immersion well assembly the immersion well is preferably made of 
quartz. Since a pyrex filter is used, also an immersion well made of pyrex (borosilicate) 
could be used. 
In the case of the immersion well assembly the photochemical reactor may further 
comprise a thermostat 10 for cooling the immersion well 9. Thus, this photochemical 
reactor comprises or consists of: 
a light source 11, 
an immersion well 9 surrounding the light source 11, 
a thermostat 10 for cooling the immersion well 9, 
a filter 8 surrounding the light source 11 and 
multiple loops of a tubing 7 wrapped tightly around the filter 8, the tubing 7 
having an inlet for a mixture of dihydroartemisinic acid and oxygen on its one 
end and an outlet for the reacted products on the opposite end. 
In the case of the immersion well assembly the light source is preferably a Hg lamp and 
more preferably a medium pressure Hg lamp (such as Ace Glass, UV 450 immersion 
lamp, 5 in arc, radial lead, 7825-34 ). However the use of mercury lamps is not 
mandatory, also LEOs, fluorescent lamps or halogen lamps could be used. 
In the case of the immersion well assembly the use of a 450 W Hg lamp is preferred. In 
general the power range can be from 1 00 W to 1200 W. Lamps having the powers of 1 00 
W, 200 W, 450 W, 500 Wand 1200 Ware easily commercially available. 
In the case of the immersion well assembly the light source needs an adapted power 
source 12. For such an Ace Glass lamp an Ace Glass, 7830 power supply is preferred. 
However, any power source supplying this power could be used. 
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In the case of the immersion well assembly, the inventive photochemical reactor may 
optionally further comprise a thermostat for cooling the immersion well. 
The thermostat is for example a Huber, Unistat 360. Any cooling system able to cool 
down the lamp at the desired temperature could be used. For example another 
photochemical reactor uses a Julabo FL601. Also, one cooling system could be used for 
more than one photochemical reactor. 
In the case of the immersion well assembly, the present invention furthermore refers to a 
continuous flow reactor as depicted in Figures 1 and 2 for the production of artemisinin (6) 
from dihydroartemisinic acid (2) comprising or consisting of 
the photochemical reactor described before, 
a first mixer 6a, connected to the inlet of the tubing 7 of the photochemical reactor, 
a feed F1 for a solution of dihydroartemisinic acid, 
a first pump 1a for pumping the solution of dihydroartemisinic acid to the first mixer 
6a, 
a check-valve 5a between the first pump 1 a and the first mixer 6a, 
an oxygen tank 4 with a manometer 3, 
a mass flow controller 2 disposed between the oxygen tank 4 and the first mixer 6a 
for controlling the oxygen flow rate, 
a check valve 5b between the mass flow controller 2 and the first mixer 6a, 
a feed F2 for an acidic solution, 
a second mixer 6b connected to the outlet of the tubing 7 of the photochemical 
reactor and to the feed F2 of the acidic solution, 
a second pump 1 b for pumping the acidic solution to the second mixer 6b, 
at least one reactor 15 for producing or completing the synthesis of artemisinin, 
connected downstream to the second mixer 6b, and 
a collection flask 18 for collecting the artemisinin-containing solution from the at 
least one reactor 15. 
In the case of the immersion well assembly and the box assemblies it is evident to a skilled 
person that the continuous flow reactor of the present invention also may comprise, for 
instance, tubing for connecting said parts or fastener and clamps for fixating the single 
components of the continuous flow reactor. However these parts are not essential to the 
invention and thus are not explicitly mentioned in the patent claims. 
In an alternative embodiment the acidic solution flows from its feed F2 not to the second 
mixer 6b but to the first mixer 6a and the second pump 1 b is not arranged between the 
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feed F2 for the acidic solution and the second mixer 6b but between the feed F2 for the 
acidic solution and the first mixer Ga. 
In the case of the immersion well assembly and the box assemblies it is preferred that the 
pumps are HPLC pumps. More preferred are models such as a Vapourtec R2C+ unit. 
Any HPLC pumps or pumps for continuous flow systems can be used such as Syrris 
pumps. For certain embodiments an acid resistant pump is required in order to pump the 
solution of the acid such as the TFA solution. 
The mass flow controller is preferably from Influx, SVIB5-AI05. It allows the control of the 
flow rate from 5-90 cm3/min. Any mass flow controller allowing to control this range of 
flow rates can be used. 
The oxygen tank can be for example an Air Liquide, 02 (99.995% pure). However the 
purity of the oxygen is not important. Also air instead of 99.9% pure oxygen worked well. 
The check-valves are preferably from IDEX Health and Science, inline check-valve CV-
301 0. The use of check-valve is preferred but not essential. Any check-valve can be 
used. The check-valve was used in order to prevent the solvent to go into the mass flow 
controller. 
For both mixers ETFE T-mixers are preferred. Particularly preferred is a IDEX Health and 
Science, P-632. The ETFE T-mixers are preferred, because the material has high 
corrosion resistance and strength over a wide temperature range. Other polymers having 
similar properties could be used. The T-mixers could also be changed for mixers that 
have other shape, for example a Y-mixer. 
The tubing of the inventive device apart of the photoreactor is preferably of FEP. This 
tubing was selected for its high transmittance and stability in the UV-vis light range, its 
flexibility and its high chemical resistance. Any polymer having these properties could be 
used instead of FEP. 
For the cleavage and triplet oxygen oxidation at least one PTFE reactor is preferred. 
Preferably two reactors (15, 16) are used which preferably have different temperatures for 
processing the intermediate products. For the first reactor 15 it is preferred that it has a 
volume of 10 ml to 60 ml and more preferably of 16 to 32 ml, Omnifit, outside diameter 
(OD) 1/16 in and inside diameter (ID) 0.8 mm). This first reactor 15 is preferably kept at 
room temperature. 
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Moreover, the inventive continuous flow reactor may further comprise a second reactor 16 
downstream to the first reactor 15. This second reactor 16 is preferably kept at a 
temperature between 50°C and 70oc and more preferably at about 60°C. For the optional 
second reactor 16 it is preferred that it is a 10 ml reactor from Vapourtec, R4 unit. Any 
device able to heat a reactor to a temperature between 50°C and 70oc and preferably to 
60 oc could be used instead of the Vapourtec R4 unit, for example, other commercially 
available continuous flow systems, oil bath or water bath with an heating plate or a heating 
mantle. 
In another embodiment of the present invention three reactors (15, 16, 17) are used which 
preferably have different temperatures for processing the intermediate products. For the 
first reactor 15 it is preferred that it has a volume of 5 ml to 20 ml and more preferably of 
5 ml to 8 ml, Omnifit, outside diameter (OD) 1/16 in and inside diameter (ID) 0.8 mm). 
This first reactor 15 is preferably cooled to 0°C. The inventive continuous flow reactor 
may further comprise a second reactor 16 downstream to the first reactor. For the 
optional second reactor 16 it is preferred that it is a 10 ml to 60 ml reactor and more 
preferably a 25 ml to 30 ml reactor. This second reactor 16 is preferably used at room 
temperature. Moreover, the inventive continuous flow reactor may further comprise a 
third reactor 17 downstream to the second reactor 16. This third reactor 17 is preferably 
kept at a temperature between 50°C and 70oc and more preferably at about 60°C. For 
the optional third reactor 17 it is preferred that it is a 5 ml to 60 ml reactor and more 
preferably a 1 0 ml reactor such as from Vapourtec, R4 unit. Any device able to heat a 
reactor at about 60°C could be used instead of the Vapourtec R4 unit, for example: other 
commercially available continuous flow systems, oil bath or water bath with a heating plate 
or a heating mantle. 
Also, it is preferred that before the reaction mixture is led to the collection flask 18 a back-
pressure regulator 14 is incorporated into the immersion well assembly. Such a back 
pressure regulator can also be incorporated into other reactor assemblies such as the box 
assembly or the cooled box assemply. The optional back-pressure regulator needs to be 
acid resistant and is preferably from Vapourtec. It operates most preferably at 2.2 bar, but 
is adjustable for the inventive method in a preferred range from 0 to 8 bar. Any acid 
resistant back-pressure regulator operating in that range of pressure could be used 
instead of the one provided by Vapourtec. 
Thus, the present invention is also related to artemisinin (6) produced or synthesized 
according to the method disclosed herein. More preferably the present invention is 
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directed to artemisinin (6) produced or synthesized according to the method disclosed 
herein using the continuous flow reactor as disclosed herein. 
Optionally, the inventive continuous flow reactor may further comprise an automated two 
inlet switch valve 13a for regulating the composition of the feed F1 for the solution of 
dihydroartemisinic acid (2), allowing for rapid switching from pure solvent to the solution 
containing the dissolved dihydroartemisinic acid (2). A similar switch valve 13b can be 
disposed in the feed F2 of the acidic solution (for instance a TFA solution) in order to 
regulate the composition by portioning the stem solution of the acidic solution and the 
respective solvent. Any valves could be used, as long as they are resistant against 
corrosion and acids. 
In Fig. 1 a schematic drawing of an inventive photochemical reactor according to the 
immersion well assembly is depicted. The photochemical reactor is the central piece of 
the continuous flow reactor according to the invention. In the center of the photochemical 
reactor is a light source, preferably an Hg lamp. The light source has an oblong shape. 
Its longitudinal axis is vertical. However, the photochemical reactor could also be used in 
the horizontal orientation, i.e. where its longitudinal axis is horizontal. The lamp is 
disposed centrally in an immersion well that surrounds the lamp in a cylinder-like shape. 
At a certain distance (for instance, the outer diameter of the immersion well is 4.83 em and 
the inner diameter of the pyrex filter is 4.85 em, so the distance between the two should be 
0.01 em) a further cylinder-like shape surrounds the immersion well, having the same 
central point. This structure is a filter, preferably a Pyrex filter. Around this filter multiple 
loops of tubing are wrapped in a spiral like form. Thus the outer diameter of the filter 
determines the inner diameter if these loops. The number of loops can be variable. The 
distance between the loops is preferably equidistant but this is not compulsory. There are 
preferably two layers of loops, the first layer (the closest to the lamp) is made of, for 
instance, approximately 135 loops and the second layer of, for instance, approximately of 
115 loops, so that the complete tubing consists of approximately 250 loops. However, the 
tubing preferably consists of 1 00 to 1 000 loops in one, two or three layers, preferably of 
150 to 500 loops in one, two or three layers, more preferably of 200 to 400 loops in one, 
two or three layers, still more preferably of 220 to 300 loops in one, two or three layers, 
and most preferably of 230 to 270 loops in one, two or three layers. Moreover two or 
three layers of loops and more preferably two layers of loops are preferred. It is also 
preferred that there is no distance between the loops. At the upper end of the tubing 
there is a connection to a mixer in which dihydroartemisinic acid and oxygen are mixed. 
At the lower end of the tubing there is an outlet for the reaction products for further 
processing. For this process the addition of an acidic solution such as TFA solution is 
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needed. This addition can take place in the mixer together with the dihydroartemisinic 
acid and the oxygen, or alternatively when the products have left the photoreactor. 
Fig. 2 and 4 show the continuous flow reactor setup according to the immersion well 
assembly for the synthesis of artemisinin (6) starting from dihydroartemisinic acid (2). The 
continuous flow reactor for the synthesis of artemisinin (6) consists of two pumps 1a and 
1b, a mass flow controller 2 connected to a manometer 3 fixed on an oxygen tank 4 and a 
check-valve 5a between the pump 1 a and another check valve 5b between the mass flow 
controller 2 and the mixer 6a. The center piece of the continuous flow reactor is a 
photochemical reactor with the mixer 6a and multiple loops of a tubing 7 wrapped tightly 
around a filter 8, which surrounds an immersion well 9, optionally cooled by a thermostat 
10, a light source 11, a power supply 12 for the photochemical lamp 11, a second mixer 
6b, a reactor 15, preferably a second reactor 16, preferably a third reactor 17 and a 
collection flask 18. The flow reactor setup comprises preferably in addition an automated 
two inlet valve 13 allowing for rapid switching from pure solvent to the solution containing 
the dissolved reagents at the intake pump and optionally a back-pressure regulator 14 
which was installed in order to increase the internal pressure of the system. All the parts 
are connected with tubing. 
In a preferred embodiment as depicted in Figure 11 the immersion well assembly as 
depicted in Figure 2 can further comprise an additional pressure regulator 14a between 
the photochemical reactor and the second mixer 6b. 
FEP tubing was preferably selected for its high transmittance and stability in the UV-vis 
light range, its flexibility and its high chemical resistance. The 2 mm thick Pyrex filter was 
advantageous to absorb wavelengths below 300 nm, to prevent degradation of the tubing, 
and to avoid any undesired side reactions involving short wavelength light. The 
temperature in the tube during the reaction is estimated to range preferably from 25 to 
30°C, based on temperature of the cooling liquid, which circulate in the immersion well, 
between the lamp and the filter. For safety reasons, the lamp was placed inside an 
aluminum box for blocking UV irradiation. Two fans can optionally be installed for 
additional cooling. 
A solution of dihydroartemisinic acid (2) and the photosensitizer in dichloromethane was 
mixed (2.5 ml/min) with a flow of oxygen gas (7.5 ml/min) and passed through the above 
described photoreactor. The residence time in the reactor is approximately 2.0 minutes. 
Using a Vapourtec R2C+ pump, a solution of TFA in toluene was added at a flow rate of 
0.5 ml/min with the outlet stream of the photochemical reactor containing mainly 
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intermediate (3) to induce the acid catalyzed Hock cleavage. A PTFE reactor (having two 
components: a 16 mL volume kept at room temperature and a 10 mL volume heated at 
about 60°C) resulted in approximately 2.5 min residence time to achieve also the reaction 
of triplet oxygen and further condensation. After a total residence time of 4.5 min the 
product stream containing mainly desired artemisinin (6) was obtained. Purification by 
chromatography was performed. The overall yield of (6) in the multistep reaction from 
dihydroartesiminic acid (2) is 39% with a productivity of 200 g of the anti-malaria 
compound per day. A rough calculation based on 300 million doses of artemisinin needed 
per year reveals that approximately 2050 photoreactors are needed to meet the demand, 
even if no further improvements are made to the process described here. 
Box assembly 
The present invention also refers to a device in which the inventive process of producing 
artemisinin takes place. In the case of the box assembly (Fig. 5 and Fig.6), the invention 
refers to a continuous flow reactor comprising a photochemical reactor for the production 
of artemisinin (6) from dihydroartemisinic acid (2) comprising or consisting of 
a light emitting diode module (LED module) 23 which is lighting the transparent 
body 21 in a frontal direction of lighting 25, 
a LED module 23 in which the arranged LED's 24 are face to face to the 
transparent body 21 
a box 20 which is preferably lightproof, 
a transparent body 21 which is wrapped by a FEP tubing 22 
multiple loops of a tubing 22 wrapped tightly around the transparent body 21, the 
tubing 22 having an inlet 29 for a mixture of dihydroartemisinic acid and oxygen 
on its one end and an outlet 26 for the reacted products on the opposite end. 
The transparent body 21 in front of the LED module 23 has preferably a square and plane 
shape. The surface of the inner box wall 27 has preferably a light reflecting property as it 
may consist of an aluminium foil. 
In the case of the box assembly the photooxidation of dihydroartemisinic acid (2) was 
explored in a home-built continuous flow reactor as shown in Figures 5 and 6, comprising 
a photochemical reactor consisting of fluorinated ethylene propylene (FEP) tubing 
wrapped around a transparent body (preferably a panel of polycarbonate) which is placed 
inside a box, whereby the inner box also contains a light source wherein light source of the 
box assembly is an assembly of light-emitting diodes which have a light emitting 
wavelength of 420nm or 660nm. Preferred is tubing of the photochemical reactors having 
a volume between 10 ml and 30 mi. A solution of dihydroartemisinic acid (2) in an organic 
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solvent was added via a HPLC pump and oxygen was delivered via a mass flow controller 
connected to a gas cylinder. The solution of (2) and the oxygen gas were mixed using a 
ethylene tetrafluoroethylene (ETFE) T-mixer. Tetraphenylporphyrin (TPP) was used as 
photosensitizer due to its high quantum yield and high stability against photo-bleaching. 
The inner walls of the box contain a light reflecting aluminum foil surface. 
The technical values according to the box assembly may be described as shown in Table 
2: 
Table 2 
Use of with 660 nm LED and methylene blue: 
light output 8,7 w electric output 46 w 
photon flow: 2,88 mmol/min quantum yield 10 2 0,52 
singlet 02: 1,50 mmol/min 2,16 mol!d 
selectivity artemisinin: 0,4 mass/day: 243,38 g/d 
light output for 1 kg artemisinin: 0,86 kWh 
electric output for 1 kg: 4,54 kWh 
Use of 420 nm LED and tetraphenylporphyrin: 
light output 12 w electric output 72 w 
photon flow: 2,53 mmol/min quantum yield 10 2 0,63 
singlet 02: 1,59 mmol/min 2,292 mol!d 
selectivity artemisinin: 0,4 mass/day: 258,82 g/d 
light output for 1 kg artemisinin: 1,11 kWh 
electric output for 1 kg: 6,68 kWh 
In Fig. 5 a schematic drawing of a continuous flow reactor with a focus on the 
photochemical reactor according to the box assembly is depicted. In the box assembly 
the central piece of the continuous flow reactor is the wrapped transparent body 21 which 
is lighted by the LED module 23 according to the invention. The photochemical reactor of 
the box assembly comprises a setup which consists of a tube made of a fluorinated or 
perfluorinated alkylene polymer 22 wherein the photooxidation of dihydroartemisinic acid 
takes place and which is wrapped around a transparent body 21, which is placed inside a 
box 20, wherein the box also contains a light source. The light source is an assembly of 
arranged LED's 24 which are part of the LED module 23. The light-emitting diodes have 
a preferred light emitting wavelength of 420nm and/or 660nm. The setup of the arranged 
LED's 24 are within a plane module having an emission-surface within 0.5 x 0.5 cm2 to 20 
x 20 cm2, or even more preferred of at least 2.5 x 2.5 cm2 . Within the box assembly 
containing the light source and the tubing wrapped around a transparent body, more than 
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one module of light emitting diodes 23 may be arranged around the wrapped tubing, 
containing the dihydroartemisinic acid (2) and the oxygen for the photooxidation reaction. 
The inner walls of the box 20 containing the tubing 22 and the light source, have a light 
reflecting surface 27 wherein in another embodiment of the invention the box 20 may also 
contain reflectors, having a light reflecting surface, wherein the reflectors are arranged 
around the tubing and the light source. The light reflecting surface and/or the reflectors 
lead to a specular reflection of the light of the arranged LED's 24 within the box 20. 
Moreover the light reflecting surface and/or the reflector may be made out of a light 
reflecting material which has a light reflectivity of at least >70 %, or more preferably >90%, 
wherein the reflected light spectra comprises the wavelengths needed to perform the 
photooxidation reaction of dihydroartemisinic acid (2). In a preferred embodiment of the 
invention the reflected spectra in the box assembly contains the wavelengths of 420nm 
and/or 660nm. 
According to a preferred embodiment as depicted in Figure 12 the continuous flow reactor 
as depicted in Figure 5 can further comprise an additional pressure regulator 14a at the 
outlet of the photochemical reactor. 
The number of loops of the wrapped tubing 22 can be variable. The distance between the 
loops is preferably equidistant but this is not compulsory. There are preferably two layers 
of loops, the first layer (the closest to the lamp) is made of, for instance, approximately 135 
loops and the second layer of, for instance, approximately of 115 loops, so that the 
complete tubing consists of approximately 250 loops. However, the tubing preferably 
consists of 100 to 1000 loops in one, two or three layers, preferably of 150 to 500 loops in 
one, two or three layers, more preferably of 200 to 400 loops in one, two or three layers, 
still more preferably of 220 to 300 loops in one, two or three layers, and most preferably of 
230 to 270 loops in one, two or three layers. Moreover two or three layers of loops and 
more preferably two layers of loops are preferred. It is also preferred that there is no 
distance between the loops. At the upper end of the tubing there is a connection to a 
mixer 28 in which dihydroartemisinic acid and oxygen are mixed. At the lower end of the 
tubing there is an outlet 26 for the reaction products for further processing. For this 
process the addition of an acidic solution such as TFA solution is needed. This addition 
can take place in the mixer together with the dihydroartemisinic acid and the oxygen, or 
alternatively when the products have left the photoreactor. 
- The box 20 is preferably light proof, preventing electromagnetic radiation from leaving 
or entering the box. In a most preferred embodiment only the openings through 
which the tube enters and leaves the box are the only two openings through which 
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light might be able to leave or enter the box. The box assembly can comprise any 
housing capable of accommodating at least the photochemical reactor consisting of 
or comprising the transparent body 21 and wrapped tubing 22 as well as the light 
source consisting of or comprising the LED module 23 and the arranged LEOs 24. 
However, also other reactor components can be accommodated into the box of the 
box assembly. The box preferably comprises connection points and/or connectors 
for the tubing inlets (29) and outlets (26), as well as connection points and/or 
connectors for electric cables or support cables for the operation of the LED-module 
or modules 23 and other internal devices that need electricity (e.g. motors or electric 
valves). In a further embodiment of the invention the box assembly may further 
comprise a series connection of several transparent bodies 21 wrapped by the tubing 
22, wherein this assembly of wrapped bodies may preferably be surrounded by more 
than one LED modules 23, whereby the surrounding by LED-modules 23 may be 
performed in a cylindrical or spherical orientation around the wrapped bodies 21. 
The box 20 may further comprise electric motors which may be used for the 
alignment of the LED-modules 23 and the reflectors used for reflecting the LED-light 
back onto the tubing 22. In another embodiment of the invention the box may also 
comprise further valves within the tubing 22 for the feeding or drainage of reactants 
during the photooxidation reaction of dihydroartemisinic acid (2). In another 
embodiment of the invention the box 20 may also comprise or have an opening that 
can be closed off by means of a light proof cover, wherein the opening maybe used 
for the maintenance of the inner parts of the box, which may comprise the LED 
module or modules 23, the tubing 22, the transparent body or bodies 21, reflectors or 
reflecting surface of the inner wall 27, the motors used for alignment or valves within 
the tubing 22. In another embodiment of the invention the transparent body 21 may 
be made out of a transparent material belonging to the group comprising: 
architectural glass, borosilicate glass, calcite, cellophane, cellulose acetate, cer-vit, 
fused quartz, germanium dioxide, iceland spar, monopotassium phosphate, 
nitrocellulose, polastarch material, poly(methyl methacrylate), polycarbonate, 
polyethylene, polyethylene terephthalate, polylactic acid, polyvinyl butyral, pyrex, 
sitall, soda-lime glass, transparent ceramics, vycor, zerodur, and whereby the 
transparent material is preferably transparent in the wavelength region necessary for 
the photooxidation reaction of dihydroartemisinic acid (2), which is even more 
preferably 420 nm and/or 660 nm. In another preferred embodiment of the invention 
the transparent material of the transparent body 21 has a transparency of at least 
>70%, and even more preferably >90% in the wavelength region necessary for the 
photooxidation reaction of dihydroartemisinic acid (2). 
wo 2013/030247 PCT/EP2012/066800 
64 
The inventive photochemical reactor is a box made of lightproof or opaque material in 
which the photochemical reaction is carried out. The box has one small opening so that 
the tube for the reaction mixture can be inserted into the box and another small opening 
through which the tube with the reaction mixture after the photochemical reaction can 
leave the box. At least one light source and preferably LED light sources or LED modules 
are located or placed or arranged inside the box in order to provide the photochemical 
activation for the photochemical oxidation of dihydroartemisinic acid (2) with singlet 
oxygen. The tubing 7 runs in multiple loops through the inside of the box in order to 
ensure that the reaction mixture containing the starting materials has sufficient time to 
react so that an as much completed conversion of the dihydroartemisinic acid (2) as 
possible is obtained. The tubing 7 is preferably wrapped around a transparent body or 
any transparent support so that the single loops are exposed to the light equally. The 
transparent body or transparent support is translucent, i.e. is light-transmissive so that the 
tubing is exposed to light in the most effective manner. 
It is within the general skills of a person skilled in the art to determine which flow rate, 
inside diameter of the tubing 7 and length of the tubing 7 inside the box and/or number of 
loops around the transparent body, kind of light source, wavelength of the emitted light 
and, for instance, electrical output of the light source is required to obtain an almost 
complete conversion of the dihydroartemisinic acid (2) when running through the tubing 7 
and through the inside of the box of the photochemical reactor. 
Especially preferred are photochemical reactors and continuous flow reactors which allow 
performing the synthesis of artemisinin in a continuous manner. As explained above, this 
contrary to a batch-wise reactor design, which only allows performing the reactions batch-
wise, i.e. performing the synthesis of artemisinin in batches. 
Cooled box assembly 
Another preferred embodiment of the present invention refers to a system which will be 
referred to herein as cooled box assembly. This flow reactor setup comprises a specific 
cooled box reactor 30 for the photooxidation reaction and further reactor compartments 34 
and 35 for the acid mediated Hock cleavage and the subsequent oxidation. The center 
piece of the cooled box assembly is the reactor system which comprises additionally 
compared to the reflective box housing of the box assembly a cooling system capable of 
cooling the reactor comprising at least a transparent body 21 wrapped by the tubing 22 as 
described above. 
In the cooled box assembly the reactor is immersed into a cooling liquid, preferably with 
the entire body of the reactor. The cooling liquid is capable of being liquid at low 
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temperatures, preferably below ooc, more preferably below -10 oc, even more preferably 
below -20°C, yet even more preferably below -50 oc and most preferably below -1 00°C. 
In a preferred embodiment the cooling liquid is a mixture of water and an organic solvent. 
However, the cooling liquid may also be a fluorinated hydrocarbon or a solution of water 
and an inorganic salt such as sodium or potassium chloride. In a preferred embodiment 
the cooling liquid is a mixture of water and ethylene glycol in a ratio 2:3 (v/v). Other 
preferred ratios are water to ethylene glycol range from 0.5:100 to 4:1. Other preferred 
organic solvents for preparing a cooling liquid with water are methanol, ethanol, 
isopropanol, acetone, DMSO and glycerol. The cooling liquid is filled into the main body 
of the cooled box assembly which can be any suitable containment being water proof and 
capable of keeping a certain amount of liquid such as a container, a bucket, a tray, a 
vessel or a bowl, preferably equipped with reflectors or with a reflecting surface on the 
inner wall. For the cooled box assembly the main body containment is preferably made of 
aluminum or stainless steel. However, also other materials are suitable such as 
chromium, molybdenum, silver, gold, lead or alloys thereof. 
Further immersed into the cooling liquid is a chiller 33 capable of cooling the liquid from 
room temperature down to the freezing point of the cooling liquid. Depending on the 
cooling liquid temperature down to -100 oc can be achieved. Preferable temperature 
range for the photooxidation reaction range from room temperature to -30°C, more 
preferably from 10 oc to -25 °C, even more preferably from 0 octo -20 °C, yet even more 
preferably from -10 octo -20 oc, and most preferably from -15 octo -18 °C. 
The cooled box assembly as also depicted in Figure 8 may further comprise a high energy 
LED module or modules 31 with a corresponding energy source 32. However, it is also 
possible that the cooled box assembly comprises a LED module or modules 23 as used 
for the box assembly. The high energy LED module 31 is embedded into one wall of the 
main body containment 30, preferably the ceiling wall with a defined distance to the reactor 
being immersed into the cooling liquid. The distance between the LED module 31 and the 
reactor is preferably between 1 em and 10 em, more preferably between 2 em and 5 em 
and most preferably 3 em. The high energy LED module 31 comprises light-emitting 
diodes having a preferred light emitting wavelength of 420 nm and/or 660 nm. The setup 
of the arranged LED's for 31 are within a plane module having an emission-surface within 
25 x 120 cm2 to 50 x 50 cm2, or even more preferred of at least 44 x 88 cm2. The 
emission angle of the diodes ranges from goo to 150°, and is preferably 120°. The optical 
output of the high energy LED module 31 is up to 400 Wand preferably ranges from 200 
to 350 W, and is most preferably 280 W. 
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After passing through the chilled reactor comprising at least a transparent body 21 
wrapped by the tubing 22 the reaction mixture exits the main body containment 30 into a 
tubing 22a which is preferably larger in diameter than the tubing 22. The diameter of the 
tubing 22a is preferably 1.5 to 3 fold of the diameter of tubing 22, more preferably 1.8 to 
2.5 fold of the diameter of tubing 22, and most preferably 2 fold of the diameter of the 
tubing 22. The reaction mixture flows through tubing 22a in reactor component 34 being 
kept at a decreased temperature ranging from 0 oc to 15 oc, and preferably being 10 °C. 
In a preferred embodiment the reaction volume kept at the decreased temperature of 
reactor component 34 is 10 mi. Subsequent to the reactor component 34 there is a 
reactor component 35 kept at a temperature ranging from 20 oc to 30 oc, and preferably 
kept at room temperature. The reaction volume of the reactor component 35 is preferably 
2 to 6 fold of the reaction volume of reactor component 34, more preferably 3 fold of the 
reaction volume of the reactor component 34. 
At the end of the reactor assembly there is provided a back pressure regulator 14 capable 
of increasing the pressure within the reaction system beneficially influencing the oxygen 
solubility and thereby the oxygen concentration in the reaction mixture. 
According to a preferred embodiment as depicted in Figure 13 the continuous flow reactor 
of the cooled box assembly as depicted in Figure 8 can further comprise an additional 
pressure regulator 14a at the outlet of the photochemical reactor and a second additional 
pressure regulator between reactor component 34 and reactor component 35. 
Thus, the cooled box assembly of the present invention preferably comprises as shown in 
Figure 8 
a feed F4 for dihydroartemisinic acid (2) and trifluoroacetic acid (TFA) and a 
suitably solvent which can be mixed at an automated two inlet switch valve 13a for 
regulating the composition of the feed 
a pump 1 a and a pressure sensor 5c, 
an oxygen tank 4 being connected to a pressure regulator 3 and a flow control 2 
being further connected to a check valve 5b, 
a T-mixer valve 28 where the feed solution of dihydroartemisinic acid and oxygen 
are mixed, 
a cooled box main containment 30 being filled with a suitable cooling liquid bearing 
the transparent body 21 wrapped by the tubing 22 in the liquid and the chiller 33, 
a high energy LED module 31 with a suitable energy source 32, 
a tubing 22a having a larger diameter than the reactor tubing 22, 
a reactor compartment 34 
a reactor compartment 35 
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a back pressure regulator 14 
an outlet for the reaction mixture. 
Specific embodiments of the cooled box assembly are depicted in Figure 9A and 98. 
Another embodiment of the invention comprises the continuous separation of artemisinin 
(6) out of the raw product mixture which is finally produced by the continuous flow reactor. 
Such raw product mixtures can be separated by usual techniques such as extraction or 
column chromatography. However it is also possible to implement the separation step 
into the continuous reactor design of the present invention. Herein the two subsequent 
methods are preferred: 
separation by simulated moving bed chromatography, 
separation by continuous crystallization. 
Continuous chromatography methods, in particularly simulated moving bed 
chromatography (SMB chromatography) comprises an arrangement of several columns 
with two inlet and outlet connections respectively, which are moved in such a fashion to 
mimic a counter flow of the stationary phase compared to the eluent flow. This enables 
continuous binary separations in which either the least or the strongest absorbing 
component can be extracted as pure compound. Solvents and stationary phases can be 
adjusted for the purification of artemisinin from the crude mixture exiting from a reactor of 
the present invention after performance of the Hock cleavage upon formation of 
artemisinin. In a preferred embodiment, the solvent for the simulated moving bed 
chromatography is a mixture of dichloromethane and hexane (50:50). Also, this method is 
readily scalable and can be employed for purification on large scale without extensive 
consumption of solvents. 
In the continuous crystallization process, a saturated solution of the crude in a suitable 
solvent is prepared at elevated temperatures. Cooling while flowing through a tube 
creates an oversaturated solution, from which upon seeding artemisinin crystallizes onto 
the surface of the tube. These crystals can be removed from the mixture continuously. 
Accordingly, the crude mixture containing artemisinin after performing the Hock cleavage 
exits one of the herein described reactor components and the crude solution is exposed to 
elevated temperatures, preferably under reduced pressure for removal of solvent. Once a 
sufficient amount of solvent is removed, and a saturated or almost saturated solution of 
artemisinin is prepared the solution is led to a further component of the reactor where 
decreased temperature is applied to the solution. Preferably, not only the temperature is 
decreased but also crystalline artemisinin seeds are provided. Upon these conditions an 
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oversaturated solution develops out of which crystalline artemisinin will precipitate which 
can be separated, e.g. by filtration from the crude reaction mixture. 
Cylinder assembly 
Another preferred embodiment of the present invention refers to a system which will be 
referred to herein as cylinder assembly. This flow reactor setup comprises a specific 
cylinder or a double-walled cylinder or even a multiple-walled cylinder being placed around 
the light source 11 and wherein the solution or mixture of dihydroartemisinic acid flows 
through that cylinder or within the walls of the doubled-walled or multiple-walled cylinder 
while being exposed to the light of the light source. Particularly by using a doubled-walled 
or multiple-walled cylinder the solution or mixture of dihydroartemisinic acid flows more 
than once past the light source and experiences an increased retention time. Also, 
between the walls or at one side of and/or around or within the one cylinder a cooling 
cylinder may be attached such that the solution or mixture of dihydroartemisinic acid may 
be adjusted to a certain preferred temperature at the outer side of the reactor a cylinder 
may be attached comprising a second light source such that the solution or mixture of 
dihydroartemisinic acid can be irradiated from two sides of the cylinder assembly. 
Further, in case no second light source is incorporated into the cylinder assembly the outer 
surface of the outer most cylinder is covered to the inside facing the one light source with a 
reflective material as defined herein. The different cylinders as being arranged around the 
at least one light source in the middle of the assembly are preferably made of glass, more 
preferably of pressure proof glass, such that the light can easily be irradiated without 
significant loss of intensity on the solution running through the cylinder which can further 
be processed under increased pressure, preferably oxygen pressure. 
All other reactor parts of the continuous flow reactor of the cylinder assembly may 
correspond to the herein described reactor parts in the immersion well assembly, or the 
box assembly or the cooled box assembly. 















Description of Figures 
Schematic drawing of the photochemical reactor for the synthesis of 
artemisinin according to the "immersion well assembly". 
System diagram of the continuous flow reactor for the synthesis of 
artemisinin according to the "immersion well assembly". 
1H NMR of the produced artemisinin 
Flow reactor setup for the synthesis of artemisinin according to the 
"immersion well assembly". 
Schematic drawing of "box assembly" setup of the continuous flow reactor. 
Parts of the "box assembly" setup of the continuous flow reactor. 
System diagram of the continuous flow reactor for the synthesis of 
artemisinin according to the "box-assembly". 
System diagram of the continuous flow reactor for the synthesis of 
artemisinin according to the "cooled box assembly". 
Parts of the "cooled box assembly" setup of the continuous flow reactor. 
(A) Diagram on the temperature dependence of the acid mediated cleavage, 
and (B) diagram on conversion dependency on the photosensitizer 
concentration. 
System diagram of the continuous flow reactor of Figure 2 further comprising 
an additional pressure regulator 14a. 
System diagram of the continuous flow reactor of Figure 5 further comprising 
an additional pressure regulator 14a. 
System diagram of the continuous flow reactor of Figure 8 further comprising 
an additional pressure regulators 14a and 14b. 




1H NMR spectra were recorded on a Varian 400-MR spectrometer (at 400 MHz) at 
ambient temperature. The proton signal of residual non-deuterated solvent (8 7.26 ppm 
for CHCI3) was used as an internal reference for 1H spectra. Data are reported as follows: 
chemical shift in parts per million (8, ppm), multiplicity (s =singlet, d =doublet, t =triplet, q 
= quartet, qn = quintet, m = multiplet and br = broad), coupling constant reported in Hertz 
(Hz) and integration. 13C spectra were recorded on a Varian 400-MR spectrometer (at 101 
MHz) at ambient temperature. Chemical shifts are reported in parts per million (8, ppm). 
The carbon signal of deuterated solvent (8 77.16 ppm for CDCb) was used as an internal 
reference for 13C spectra. One exemplary spectrum of artemisinin prepared by a method of 
the present invention is depicted in Figure 3. 
Infrared (IR) spectra were recorded as thin films on a Perkin-Elmer 1600 FTIR 
spectrophotometer. Melting points were recorded using an Electrothermal lA 9300 melting 
point apparatus and are uncorrected. Optical rotations (OR) were measured with a 
Schmidt & Haensch Unipol L 1000 at a concentration (c) expressed in g/1 00 ml. High-
resolution mass spectra (HRMS) were recorded with an Agilent 6210 ESI-TOF mass 
spectrometer at the Freie Universitat Berlin, Mass Spectrometry Core Facility. 
Analytical thin layer chromatography (TLC) was performed on Kieselgel 60 F254 glass 
plates pre-coated with a 0.25 mm thickness of silica gel. The TLC plates were visualized 
with UV light and by staining with an aqueous solution of potassium permanganate 
(KMn04) or a mixture of iodine and silica. Column chromatography was performed using 
Kieselgel 60 (230-400 mesh) silica gel with a typical 50-100: 1 weight ratio of silica gel to 
crude product. 








H ~e H ~e 
TPP(2mM),02(g)•11.5bar ~~ · ~~ · 
DCM (0.8 M) Me ~ 0 + ~ + 
OOH H Flow rate of solution: ,,.. OH HOO ,,.. OH 
2.5 mUmin Me' Me' 
OH 




Productivity: 1.50 mmol/min 
A solution of dihydroartemisinic acid (0.95 g, 4.0 mmol) and tetraphenylporphyrin (6.1 mg, 
10 ).lmol) in dichloromethane (total volume of the solution: 5.0 ml, volumetric flask) was 
prepared. The lamp was turned on 30 min prior to the beginning of the experiment. The 
reactor was flushed with pure dichloromethane (2.5 ml/min) and oxygen (5 ml/min, 11.5 
bar) for 5 min. The reagents were then injected at a flow rate of 2.5 ml/min and the flow 
of oxygen was readjusted to 5 ml/min (11.5 bar). After the injection of the entire solution 
of dihydroartemisinic acid, the reactor was flushed with pure dichloromethane (2.5 ml/min) 
to recover all the material. The crude material was concentrated under reduced pressure 
to remove the dichloromethane affording a mixture of the intermediate products (3), (4) 
and (5) and TPP as a green solid (1.0856 g). Part of this mixture (200 mg) was dissolved 
in CDCb and mesitylene (103 ).ll, 0.741 mmol, 98% pure) was added. 1H NMR analysis 
showed a conversion of 91% and a yield of the desired product of 75%. 
Example 2: Reaction conditions for oxidation of dihydroartemisinic acid (2) in flow and 
cleavage of tertiary allylic peroxide (3) in batch to obtain artemisinin (6) 
Me Me Me H = 
- . TPP (2 mM), 0 2(g)• 11.5 bar 
DCM (0.5 M) 
Me Flow rate solution: 
OH 2.5 mllmin 
Flow rate oxygen: 
Mem~H~O~ 6o~e''··~ I Ho6M~,,··~ 
0 5 mUmin 
Dihydroartemisinic acid 
2 
TFA (0.5 eq.), 0 2(g) 
0 °C, 2 h 
Yield: 50% 
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A solution of dihydroartemisinic acid (4) (1.18 g, 5.0 mmol) and tetraphenylporphyrin (12 
mg, 20 ).lmol) in dichloromethane (total volume of the solution: 10.0 ml, volumetric flask) 
was prepared. The lamp was turned on 30 min prior to the beginning of the experiment. 
The reactor was flushed with pure dichloromethane (2.5 ml/min) and oxygen (5 ml/min, 
11.5 bar) for 5 min. The reagents were then injected at a flow rate of 2.5 ml/min and the 
flow of oxygen was readjusted to 5 ml/min (11.5 bar). After the injection of the entire 
solution of (4 ), the reactor was flushed with pure dichloromethane (2.5 ml/min) to recover 
all material. The reaction mixture was collected in a round bottom flask and was cooled 
down to 0 °C. Oxygen was bubbled into the reaction mixture at atmospheric pressure. 
After 2 min of bubbling, TFA (0.19 ml, 2.5 mmol, 0.5 eq.) was added drop wise. The 
resulting mixture was stirred at 0 oc for 2 h, while maintaining the oxygen bubbling. Then, 
the reaction was quenched with a saturated aqueous solution of NaHC03. The resulting 
biphasic mixture was stirred at room temperature until disappearance of the green colour. 
The phases were separated and the aqueous phase was extracted with dichloromethane 
(3 times). The combined organic layers were dried over anhydrous Na2S04, filtered and 
concentrated under reduced pressure. Purification over silica gel (5% - 20% EtOAc in 
cyclohexane) afforded artemisinin (0.707 g, 50%) as a yellow solid. 
Example 3: Reaction conditions for oxidation of dihydroartemisinic acid (2) in continuous 
flow, followed by the cleavage of tertiary allylic peroxide (3) in continuous flow to obtain 
artemisinin (6) (sequential process) 
Me Me Me H = 
- - TPP (2 mM), 0 2(g)• 11.5 bar 
DCM (0.5 M) 
Me Flow rate solution: 
OH 2.5 mllmin 
Flow rate oxygen: 
Mem ~H HOO ~ .. ' 00~e'''·~ Me' 
0 5 mllmin 
Dihydroartemisinic acid 
2 
0 2(g)• 11 .5 bar 
DCM (0.5 M) 
Flow rate solution: 
2.5 mllmin 
Flow rate 0 2(9): 
5 mllmin 
Flow rate TFA: 
0.5 mllmin 
Yield: 46% 
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A solution of dihydroartemisinic acid (1.18 g, 5.0 mmol) and tetraphenylporphyrin (12 mg, 
20 ).lmol) in dichloromethane (total volume of the solution: 10 ml, volumetric flask) was 
prepared. The lamp was turned on 30 min prior to the beginning of the experiment. The 
reactor was flushed with pure dichloromethane (2.5 ml/min) and oxygen (5 ml/min, 11.5 
bar) for 5 min. The reagents were then injected at a flow rate of 2.5 ml/min and the flow 
of oxygen was readjusted to 5 ml/min (11.5 bar). After the injection of the entire solution 
of (1 ), the reactor was flushed with pure dichloromethane (2.5 ml/min) to recover all the 
material. The crude material was concentrated under reduced pressure to remove the 
dichloromethane affording a mixture of (3), (4), (5) and TPP as a green solid. 
The crude mixture was dissolved in DCM (total volume of the solution: 10 ml, volumetric 
flask). The crude mixture was injected at a flow of 2.5 ml/min and combined with oxygen 
(5 ml/min, 11.5 bar) and a solution of TFA (1.9 ml of TFA in 18.1 ml of DCM) at a flow 
rate of 0.5 ml/min with the help of a cross mixer. The reaction mixture was passed a 
PTFE reactor composed of 32 ml loop at rt and 1 0 ml loop heated at 60°C. The crude 
material was collected in a flask containing a saturated aqueous solution of NaHC03. The 
resulting biphasic mixture was stirred at room temperature until green colour disappeared. 
The phases were separated and the aqueous phase was extracted three times with 
dichloromethane. The combined organic layers were dried over anhydrous Na2S04, 
filtered and concentrated under reduced pressure. Purification over silica gel (5% - 20% 
EtOAc, in cyclohexane) afforded artemisinin (0.66 g, 46%) as a yellow solid. 








TPP (1 mM), 0 2(9), 11.5 bar 
DCM (0.5 M) 
Flow rate of solution: 
2.5 mllmin 
Flow rate of oxygen: 
7.5 mllmin 
Flow rate of the solution of TF A: 
0.5 mllmin 
Yield: 39% 




A solution of dihydroartemisinic acid (2.95 g, 12.5 mmol) and tetraphenylporphyrin (15 mg, 
0.02 mmol) in dichloromethane (total volume of the solution: 25 ml, volumetric flask) and a 
solution of trifluoroacetic acid (1.9 ml, 25 mmol) in dichloromethane (18.1 ml) were 
prepared and given into their respective feed. The Hg lamp was turned on 30 min prior to 
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the beginning of the experiment and the second portion of the photochemical reactor was 
heated at 60°C. The photochemical reactor was flushed with pure dichloromethane (2.5 
ml/min), dichloromethane (0.5 ml/min) and oxygen (7.5 ml/min, 11.5 bar) for 10 min. 
The reagents were then injected via their respective feed at a flow rate of 2.5 ml/min and 
the oxygen flow was readjusted to 7.5 ml/min (11.5 bar). Both streams joined in the first 
mixer. From there they entered the photochemical reactor. The TFA solution was injected 
at the exit of the photochemical reactor into a second mixer at a flow rate of 0.5 ml/min 
and the resulting mixture was pushed into the thermal reactor. The crude material 
containing the produced artemisinin was collected in a flask containing a saturated 
aqueous solution of NaHC03. The resulting biphasic mixture was stirred at room 
temperature until the green color disappeared. Phases were separated and the aqueous 
phase was extracted with dichloromethane (3 times). The combined organic layers were 
dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. 
Purification over silica gel (5% - 20% EtOAc, in cyclohexane) afforded artemisinin (1.36 g, 
39%) as a off-white solid. Further purification by recrystallization in cyclohexane afforded 
white needles. 1H NMR (400 MHz, CDCb) 8 5.86 (s, 1 H), 3.40 (dq, J = 7.3, 5.4 Hz, 1 H), 
2.47-2.39 (m, 1 H), 2.08-1.98 (m, 2H), 1.91-1.86 (m, 1 H), 1.81-1.74 (m, 2H), 1.51-1.34 (m, 
3H), 1.45 (s, 3H), 1.21 (d, J = 7.3 Hz, 3H), 1.11-1.04 (m, 2H), 1.00 (d, J = 6.0 Hz, 3H). 
The 1H NMR spectrum of the obtained artemisinin (6) is shown in Fig. 3. Mp = 153-154 
°C. [a]~ +66.3 o (c 0.97, CHCb). 13C NMR (1 01 MHz, CDCb) 8 172.2, 1 05.5, 93.9, 79.6, 
50.2, 45.1, 37.7, 36.1, 33.8, 33.0, 25.4, 25.0, 23.6, 19.9, 12.7. IR (film) v 2960, 2933, 
2860, 1731, 1112, 991 cm-1. HRMS calcd for C1sH220s (M+) 282.1467, found 282.1463. 
MS (EI) m/z 282 (1) [M+], 250 (5), 192 (70), 150 (40), 55 (63), 43 (1 00). Spectral data 
were in agreement with published data (Yadav, J. S.; Satheesh, B.; Sabitha, G. 
Tetrahedron Lett. 2003, 44, 387-389.). 
Example 5: Flow reactor setup for the synthesis of artemisinin according to example 4 
The flow reactor setup for the synthesis of artemisinin (6) consists of a feed F1 for a 
solution of dihydroartemisinic acid (2), an automated two inlet switch valve 13a for 
regulating the composition of the feed for the solution of dihydroartemisinic acid (2), 
allowing for rapid switching from pure solvent to the solution containing the dissolved 
dihydroartemisinic acid, a first HPLC pump 1a (Vapourtec, R2C+ unit) downstream to 
switch valve 13a, pumping the dihydroartemisinic acid (2) solution with a throughput of 2.5 
ml/min to the first ETFE T-mixer 6a (IDEX Health and Science, P-632) for mixing the 
dihydroartemisinic acid (2) solution and the oxygen, a first check-valve 5a (IDEX Health 
and Science, inline check-valve CV-3010) between the first HPLC pump 1a and the mixer 
6a, a mass flow controller 2 (Influx, SV1 B5-AI05, allowing control of the oxygen flow rate 
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from 5-90 cm3/min) connected to a manometer 3 fixed on an oxygen tank 4 (Air Liquide, 
02 99.995% pure), thus generating a steady oxygen flow of 7.5 ml/min, another check 
valve 5b (IDEX Health and Science, inline check-valve CV-3010) between the mass flow 
controller 2 and the first mixer 6a, multiple loops of FEP tubing 7 (20 ml, IDEX Health & 
Science, fluorinated ethylene polymer 1520, natural color, outside diameter (OD) 1/16 in 
and inside diameter (ID) 0.030 in) wrapped tightly around a Pyrex filter 8 (inner diameter 
4.5 em and wall thickness 0.2 em) which surrounds the quartz immersion well 9 cooled by 
a thermostat 10 (Huber, Unistat 360), a medium pressure Hg lamp 11 (Ace Glass, UV 450 
immersion lamp, 5 in arc, radial lead, 7825-34), a power supply 12 for photochemical lamp 
11 (Ace Glass, 7830), a second ETFE T-mixer 6b IDEX Health and Science, P-632), a first 
PTFE reactor 15 (11 ml, Omnifit, outside diameter (OD) 1/16 in and inside diameter (I D) 
0.8 mm), a second PTFE reactor at room temperature 16 (5 ml, Vapourtec), a third 
heated (60°C) PTFE reactor 17 (1 0 ml, Vapourtec, R4 unit) and a collection flask 18 for 
collecting the synthesized artemisinic acid. A feed F2 for the TFA solution is regulated via 
an automated two inlet switch valve 13b for regulating the composition of the feed for the 
TFA solution, allowing for rapid switching from pure solvent to the TFA solution. A second 
HPLC pump 1 b (Vapourtec, R2C+ unit) pumps TFA with a throughput of 0.5 ml/min to into 
the second mixer 6b disposed at the outlet of the tubing 7 of the photochemical reactor. 
There the TFA is reacted with the products of the photochemical reactor process. A back-
pressure regulator 14 of 2.2 bar (Vapourtec) was installed in order to increase the internal 
pressure of the system. FEP tubing was selected for its high transmittance and stability in 
the UV-vis light range, its flexibility and its high chemical resistance. The 2 mm thick 
Pyrex filter was essential to absorb wavelengths below 300 nm, to prevent degradation of 
the tubing, and to avoid any undesired side reactions involving short wavelength light. 
The temperature in the tube during the reaction is estimated to range from 25 to 30°C, 
based on temperature measurements taken between the cooling jacket and the tube. For 
safety reasons, the lamp was placed inside an aluminum box for blocking UV irradiation. 
Two fans were installed for additional cooling. 
Example 6: Synthesis of hydroperoxide (3) in continuous flow using the box assembly 
The flow reactor setup (Figure 5 and 7) for the synthesis of hydroperoxide (3) consists of 
a feed F3 for a solution of dihydroartemisinic acid (2), a pumping unit analogously to 
example 5 (consisting of an automated two inlet switch valve 13a for regulating the 
composition of the feed for the solution of dihydroartemisinic acid (2), allowing for rapid 
switching from pure solvent to the solution containing the dissolved dihydroartemisinic 
acid, a HPLC pump 1a (Vapourtec, R2C+ unit) downstream to switch valve 13a), pumping 
the dihydroartemisinic acid (2) solution with a throughput of 1.25 ml/min to a ETFE T-
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mixer 28 (IDEX Health and Science, P-632) for mixing the dihydroartemisinic acid (2) 
solution and the oxygen, a mass flow controller 2 (Influx, SV1 B5-AI05, allowing control of 
the oxygen flow rate from 5-90 cm3/min) connected to a manometer 3 fixed on an oxygen 
tank 4 (Air Liquide, 02 99.995% pure), thus generating a steady oxygen flow of 5 ml/min, 
a check valve 5b (IDEX Health and Science, inline check-valve CV-3010) between the 
mass flow controller 2 and the mixer 28, a photochemical reactor comprising the mixer and 
a tubing inlet 29, consisting of multiple loops of FEP tubing 22 (3.8 mL, IDEX Health & 
Science, fluorinated ethylene polymer 1520, natural color, outside diameter (OD) 1/16 in 
and inside diameter (ID) 0.030 in) wrapped tightly around a transparent body 21 
(polycarbonate plate, size 9.0 x 14.0 cm2) which is irradiated by an arrangement of 60 
High Power LEOs 24 combined in an LED module 23 emitting at 420 nm (OSA Opto 
Lights, 72 W electrical power, cooled by a fan, emission area 2.5 x 2.5 cm2) or at 660 nm 
(OSA Opto Lights, 46 W electrical power, cooled by a fan, emission area 2.5 x 2.5 cm2), 
electronics for supplying a constant current to the LED module (OSA Opto Lights), a power 
supply (Manson HCS-3202) and a back-pressure regulator of 6.9 bar (IDEX Health and 
Science) installed after the tubing outlet 26 in order to increase the internal pressure of the 
system. Because the LED module does not emit UV-radiation which would lead to 
undesired side reactions, additional filters are not necessary. The wrapped FEP tubing 22 
was irradiated directly by the LED module 23, which was installed in a distance of 3 em in 
front of the transparent body 21. For maximum efficiency, the tubing was irradiated in a 
box covered with reflective material 27 (aluminium foil). No additional cooling system for 
the photochemical reactor was installed. When using the LED module emitting at 420 nm, 
the feed F3 was a solution of dihydroartemisinic acid at a concentration of 0.5 moi/L and 
the photosensitizer tetraphenylporphyrin at a concentration of 1 mmoi/L in 
dichloromethane (2.95 g dihydroartemisinic acid and 15 mg tetraphenylporphyrin, total 
volume 25 mL, volumetric flask), whereas the photosensitizer was methylene blue instead 
of tetraphenylporphyrin at a concentration of 1 mmoi/L when using the LED module 
emitting at 660 nm (2.95 g dihydroartemisinic acid and 8 mg methylene blue, total volume 
25 mL, volumetric flask). The feed was introduced at a flow rate of 1.25 ml/min and the 
oxygen flow adjusted to 5 ml/min, resulting in a nearly complete conversion of 99% 
yielding 72% of the desired hydroperoxide (3) with a selectivity of 73% (LED module 
emitting at 420 nm). When increasing the flow rate, a higher productivity is achieved, 
however at the expense of the high conversion, as shown in Table 3: 
Table 3 
flow rate feed F3 flow rate-1 conversion yield selectivity 
hydroperoxide 3 
ml/min I mmol/min min mmor1 I mmol/min 
wo 2013/030247 PCT/EP2012/066800 
77 
5 2.5 0.4 51.4% 1.29 36.7% 71.3% 
2.5 1.25 0.8 82.9% 1.04 59.2% 71.4% 
1.75 0.875 1.143 90.3% 0.79 66.7% 73.9% 
1.25 0.625 1.6 99.3% 0.62 72.7% 73.2% 
For obtaining artemisinin, the product stream leaving the photochemical reactor at the 
tubing outlet 26 can be mixed with a solution of trifluoroacetic acid at a concentration of 
1.875 moi/L in dichloromethane (1.9 ml trifluoroacetic acid in 18.1 ml dichloromethane) 
and reacted in a thermal reactor, analogously as described in example 5, injecting the 
trifluoroacetic acid solution at a flow rate of 0.25 ml/min. Alternatively trifluoroacetic acid 
can already be added to the feed solution F3 at a concentration of 0.375 moi/L. 
Example 7: Temperature dependence on photooxidation in continuous flow using the 
cooled box assembly 
For screening the temperature dependence, a solution of dihydroartemisinic acid (0.5 M, 
DHAA) and tetraphenylporphyrin (1 mM, TPP) in DCM was prepared, using benzoic acid 
as internal standard. 5 ml of this solution (1.25 ml/min) and oxygen (5 ml/min) were 
injected with the vapourtec system into a photochemical reactor (3.8 ml, inner diameter 
0.03 inch, 12 W (light output) LED lamp emitting at 420 nm). To cool the photochemical 
reactor, it was immersed in a cooled bath. The temperature remained constant during the 
experiment. Additionally, a short reaction time without cooling was investigated, whereby 
the temperature increased only slightly to 30-40 °C. After an extended irradiation time 
without cooling, the photochemical reactor became very hot (60-80 oc). A back pressure 
regulator (5 bar) was used at the end of the system. Concentration of the residual starting 
material and the peroxides was determined by NMR and conversion and selectivities 
calculated. 
The conversion of the starting material DHAA was nearly complete in all cases, with 
conversion dropping slightly with decreasing temperature, as shown in Table 4 below. For 
a long reaction time without cooling, the decreased conversion is probably indeed related 
to the enhanced temperature. The desired peroxide is always the major product. However, 
lower temperature helps in shifting the ratio of the different peroxides towards the 
preferred hydroperoxide (3). 
Besides the 3 photooxidation products it is also worth considering the amount of other side 
products. In this respect, temperature has a pronounced effect and a low temperature of-
18 oc can decrease the amount of side products to 5% (Table 4 ). At this temperature, a 
maximum selectivity of 82% for the desired peroxide is obtained. It is therefore worth to 
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cool the reactor for the photooxidation step in order to obtain a higher yield of artemisinin 
and less side products, simplifying purification as well. 
Table 4 
selectivities 
temperature conversion desired cyclizing non- other 
peroxide (3) peroxide cyclizing byproducts 
(4) peroxide ( 5) 
60-80 oc 86% 62% 10% 5% 24% 
30-40 oc 99% 73% 12% 5% 10% 
20 oc 92% 77% 11% 5% 7% 
ooc 93% 79% 11% 3% 7% 
- 18°C 86% 82% 10% 3% 5% 
Example 8: Solvent effects on the acid mediated cleavage 
The effect of different solvents was screened using a stock solution of the photooxidation 
products with TFA as acid. As stock solution, a 20 w% solution of the photooxidation 
products in DCM was prepared. 4.5 ml of various solvents were filled in vials and after 
addition of 0.5 eq TFA oxygen was bubbled through (7.5 ml/min) under stirring. After 2 
min, 0.5 ml of the stock solution was added and 02 bubbling continued for 20 minutes. 
The yield of artemisinin (referring to the initial amount of desired peroxide) and the 
concentration of the major byproducts were evaluated by NMR. In all cases full conversion 
of the hydroperoxide was observed. In polar aprotic solvents only a low yield of artemisinin 
was obtained. Here a lot of byproducts, mainly the 5-member lactone (7) but also the 
aldehyde (9), were formed. Decreasing the polarity is beneficial, as the amount of 
byproducts is drastically reduced. 
~ 
0 0 0 
5-member lactone (7) cyclized peroxide (8) aldehyde (9) 
Table 5 
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solvent artemisinin (6) 5-member lactone cyclized peroxide 
(7) (9, in % of initial 
desired peroxide) 
acetonitrile 39% 36% 7% 
DCM 69% 17% 10% 
toluene 81% 7% 8% 
cyclohexane 76% 6% 8% 
benzotrifluoride 78% 11% 9% 
1,3- 82% 8% 9% 
bis(trifl uoromethyl )benzene 
hexafluorobenzene 81% 6% 9% 
perfluorooctane'> 40% 0% 10% 
*) phase separation occurred 
Fluorinated solvents were evaluated as well, as they are characterized by high oxygen 
solubility and long lifetime of singlet oxygen, which is beneficial for the first photooxidation 
step. For the acid catalyzed reaction fluorinated aromatic compounds perform well 
concerning artemisinin yield and prevention of byproducts. Starting material and products 
were soluble in these solvents. Perfluorooctane however is not suitable, as even upon 
heating no homogeneous mixture was achieved. The danger arising from the combination 
of a flammable solvent and oxygen is less dramatic when working in flow, as only small 
amounts of oxygen are present in the microreactor when efficient ventilation is installed. 
Example 9: Temperature effects on the acid mediated cleavage 
To test the temperature dependence of the acid-catalyzed reaction cascade 4 ml of 
toluene were filled in a vial together with TFA and stirred while 02 is bubbled through (7.5 
ml/min). After 2 min 1 ml of the photooxidation stock solution containing hydroperoxides 
(3, 4, 5) was added, stirred and 02 bubbling continued for 20 minutes or a longer time as 
indicated. The concentration of artemisinin and byproducts was evaluated by NMR without 
quenching by base. After stopping the reaction, unreacted peroxide is therefore mainly 
transformed into the aldehyde byproduct in the absence of oxygen. The overall yield for 
the complete reaction starting from DHAA is shown in Figure 1 OA. 
The highest yield of artemisinin is obtained for a reaction temperature of 25 °C. Increasing 
the temperature results in a more pronounced formation of byproducts while the 
artemisinin yield decreases. At low temperature a decrease in yield is observed as well. 
Extending the reaction time could improve the artemisinin yield and decrease aldehyde 
formation (Table 6). 
Table 6 
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reaction temprc artemisinin 5-member aldehyde cyclized 
time/min (6) lactone (7) (9) peroxide (8) 
20 -15 18.0% 2.1% 21.3% 1.6% 
20 0 33.4% 2.1% 17.8% 3.7% 
20 25 59.1% 4.4% 2.5% 6.1% 
20 50 47.0% 5.5% 4.7% 7.2% 
20 75 31.2% 6.1% 9.6% 7.5% 
60 0 55.6% 2.3% 6.8% 3.0% 
120 -15 54.4% 1.8% 5.5% 3.0% 
Example 10: Effect of photosensitizers on photooxidation in continuous flow using the 
cooled box assembly 
To evaluate the optimum photosensitizer concentration, a 0.5 M solution of 
dihydroartemisinic acid in dry toluene was prepared and benzoic acid added as internal 
standard. This solution (2 ml/min) and oxygen (5 ml/min at 10 bar, 2 eq) was injected 
with the Vapourtec system into a photoreactor (7 mL tubing in 4 layers around a 
polycarbonate plate, inner diameter 0.03 inch, 12 W LED lamp 420 nm). The photoreactor 
was immersed in an ethanol-water bath, which was cooled to -20 oc with an immersion 
cooler (Huber, TC1 OOE-F-NR). The photoreactor was installed in front of the LED module 
at a distance of 3 em. The use of dry toluene is advisable, as toluene of technical purity 
contained too much water, which crystallized inside the tubing resulting in partial clogging 
and strong pressure fluctuations. This could either be prevented by employing dry toluene 
or adding acetonitrile (around 0.5% v/v) to toluene of technical purity. A back pressure 
regulator (8 bar) was applied at the end of the system, resulting in a slightly fluctuating 
system pressure of 10- 11 bar. 
The system was flushed with pure solvent and then 5 mL of the stock solution with various 
amounts of photosensitizer was injected. The solution exiting the photochemical reactor 
was collected and analyzed by NMR. The three sensitizers tetraphenylporphyrin (TPP, 
singlet oxygen quantum yield <I>11=0.63 in benzene), zinc tetraphenylporphyrin (ZnTPP, 
<I>11=0.83 in benzene) and 9,1 0-dicyanoanthracene (DCA, <1>11=1.56 in benzene) were 
evaluated at different concentrations. All these dyes absorb blue light at 420 nm. The 
quantum yield of dicyanoanthracene is >1, because the excited dye can transfer its energy 
from the excited singlet and the triplet state to oxygen. 
Conversion of dihydroartemisinic acid against sensitizer concentration is shown in Figure 
1 OB and the specific values in Table 7. Even with relatively low concentrations of TPP 
(0.05 mol%) a high conversion of dihydroartemisinic acid is achieved. Further increase in 
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the concentration slightly improves the yield. Due to the low temperature, selectivity for the 
desired hydroperoxide was 85%. 
In case of ZnTPP a higher efficiency would be expected, as the quantum yield of this 
complex is significantly larger. However, this sensitizer performs worse. A probable 
explanation was the strong photobleaching, as indicated by the colour change after 
passing the photochemical reactor. In addition to the decreased performance, also the 
selectivity for the desired hydroperoxide dropped to 82% on average. 
For low concentrations of DCA, this sensitizer compares to TPP regarding conversion. 
Table 7 
TPP ZnTPP DCA 
cone. [mM] conversion cone. [mM] conversion cone. [mM] conversion 
0,23 73% 0,205 48% 0,6 77% 
0,75 76% 0,55 53% 1,05 72% 
1 '15 74% 0,85 57% 2,45 91% 
1,95 69% 1,2 54% 3,25 88% 
1,45 55% 
2,25 55% 
Example 11: Synthesis of artemisinin (6) in continuous flow using the cooled box 
assembly 
The flow reactor setup for the synthesis of artemisinin consists of a feed for a solution of 
dihydroartemisinic acid, a pumping unit analogously to example 6 (consisting of an 
automated two inlet switch valve for regulating the composition of the feed for the solution 
of dihydroartemisinic acid, allowing for rapid switching from pure solvent to the solution 
containing the dissolved dihydroartemisinic acid, a HPLC pump (Vapourtec, R2C+ unit) 
downstream to switch valve), pumping the dihydroartemisinic acid solution with a 
throughput of 1.25 ml/min to a ETFE T-mixer (IDEX Health and Science, P-632) for 
mixing the dihydroartemisinic acid solution and the oxygen, a mass flow controller (Influx, 
SV1 B5-AI05, allowing control of the oxygen flow rate from 5-90 cm3/min) connected to a 
manometer fixed on an oxygen tank (Air Liquide, 02 99.995% pure), thus generating a 
steady oxygen flow of 5 ml/min, a check valve (IDEX Health and Science, inline check-
valve CV-301 0) between the mass flow controller and the mixer, a photochemical reactor 
comprising the mixer and a tubing inlet, consisting of multiple loops of FEP tubing (7 mL, 
IDEX Health & Science, fluorinated ethylene polymer 1520, natural color, outside diameter 
(OD) 1/16 in and inside diameter (ID) 0.030 in) wrapped tightly around a transparent body 
(polycarbonate plate, size 9.0 x 14.0 cm2) which is irradiated by an arrangement of 60 
High Power LEOs combined in an LED module emitting at 420 nm (OSA Opto Lights, 72 
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W electrical power, cooled by a fan, emission area 2.5 x 2.5 cm2), electronics for supplying 
a constant current to the LED module (OSA Opto Lights) and a power supply (Manson 
HCS-3202). The wrapped FEP tubing was irradiated directly by the LED module, which 
was installed in a distance of 3 em in front of the transparent body. For maximum 
efficiency, the tubing was irradiated in a tray made of stainless steel to reflect 
throughpassing light onto the photochemical reactor, which was immersed in this tray, 
filled with an ethanol-water bath cooled to -20 oc with the help of an immersion cooler 
(Huber, TC1 OOE-F-NR). After leaving the photochemical reactor a solution of trifluoroacetic 
acid was introduced with a second T-mixer and the help of a HPLC pump (Vapourtec, 
R2C+ unit) at a flow rate of 0.25 ml/min. The subsequent reactor was 15 ml (inner 
diameter 0.03 inch, FEP tubing), kept at 15 oc and then 30 mL (inner diameter 0.06 inch, 
FEP tubing), kept at room temperature. A back-pressure regulator of 8 bar (Vapourtec) 
was installed after the tubing outlet in order to increase the internal pressure of the system. 
The feed was a solution of dihydroartemisinic acid at a concentration of 0.5 moi/L and the 
photosensitizer tetraphenylporphyrin at a concentration of 1 mmoi/L in toluene (2.95 g 
dihydroartemisinic acid and 15 mg tetraphenylporphyrin, total volume 25 mL, volumetric 
flask). The feed was introduced at a flow rate of 1.25 ml/min and the oxygen flow adjusted 
to 5 ml/min. The solution of trifluoroacetic acid injected into the output stream of the 
photochemical reactor contains 1.93 mL trifluoroacetic acid filled up to 20 ml with toluene 
(1.25 M, volumetric flask). The output stream showed a conversion of 89% yielding 62% of 
the desired artemisinin with a selectivity of 70% (NMR of crude). 
The solution was collected and extracted twice with sat. NaHC03 to quench the acid and 
then washed with water. The organic phase was dried over anhydrous Na2S04 and 
concentrated under reduced pressure. Then hexane was added and evaporated to remove 
most of the remaining toluene. Another portion of hexane was added, the solution heated 
shortly and cooled down. The slurry was filtrated, washed with hexane and dried under 
vacuum to afford artemisinin as an off-white solid (1.713 g, 50% isolated yield). 
Example 12: Synthesis of artemisinin (6) in continuous flow using the cooled box 
assembly 
The flow reactor setup for the synthesis of artemisinin consists of a feed for a mixture of 
dihydroartemisinic acid, trifluoroacetic acid and the photosensitizer dicyanoanthracene, a 
pumping unit analogously to example 6 (consisting of an automated two inlet switch valve 
for regulating the composition of the feed for the solution of dihydroartemisinic acid, 
allowing for rapid switching from pure solvent to the feed solution containing the dissolved 
dihydroartemisinic acid, an HPLC pump (Vapourtec, R2C+ unit) downstream to switch 
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valve), pumping the dihydroartemisinic acid solution with a throughput of 1.25 ml/min to 
an ETFE T-mixer (IDEX Health and Science, P-632) for mixing the feed solution and 
oxygen, a mass flow controller (Influx, SV1 B5-AI05, allowing control of the oxygen flow 
rate from 5-90 cm3/min) connected to a manometer fixed on an oxygen tank (Air Liquide, 
02 99.995% pure), thus generating a steady oxygen flow of 5 ml/min, a check valve (IDEX 
Health and Science, in line check-valve CV-301 0) between the mass flow controller and the 
mixer, a photochemical reactor comprising the mixer and a tubing inlet, consisting of 
multiple loops of FEP tubing (7 mL, IDEX Health & Science, fluorinated ethylene polymer 
1520, natural color, outside diameter (OD) 1/16 in and inside diameter (ID) 0.030 in) 
wrapped tightly around a transparent body (glass plate, size 9.0 x 14.0 cm2) which is 
irradiated by an arrangement of 60 High Power LEOs combined in an LED module emitting 
at 420 nm (OSA Opto Lights, 72 W electrical power, cooled by a fan, emission area 2.5 x 
2.5 cm2), electronics for supplying a constant current to the LED module (OSA Opto 
Lights) and a power supply (Manson HCS-3202). The wrapped FEP tubing was irradiated 
directly by the LED module, which was installed in a distance of 3 em in front of the 
transparent body. For maximum efficiency, the tubing was irradiated in a tray made of 
stainless steel to reflect throughpassing light onto the photochemical reactor, which was 
immersed in this tray, filled with an ethylene glycol:water bath (3:2 v/v) cooled to -20 oc 
with the help of an immersion cooler (Huber, TC1 OOE-F-NR). After leaving the 
photochemical reactor the solution was passed through a reactor with 10 ml volume (inner 
diameter 0.03 inch, FEP tubing), kept at 10 oc by immersion in a water bath and then 30 
mL (inner diameter 0.06 inch, FEP tubing), kept at room temperature. A back-pressure 
regulator of 8 bar (Vapourtec) was installed after the tubing outlet in order to increase the 
internal pressure of the system. 
The feed was a solution of dihydroartemisinic acid at a concentration of 0.5 moi/L, 
trifluoroacetic acid at a concentration of 0.25 moi/L and the photosensitizer 
dicyanoanthracene at a concentration of 2.5 mmoi/L in toluene (29.5 g dihydroartemisinic 
acid, 7.13 g trifluoroacetic acid and 143 mg dicyanoanthracene, total volume 250 mL, 
volumetric flask). The feed was introduced at a flow rate of 1.25 ml/min and the oxygen 
flow adjusted to 5 ml/min. 
The solution exiting the reactor was collected and extracted twice with sat. NaHC03 to 
quench the acid and then washed with water and brine. The organic phase was dried over 
anhydrous Na2S04 and concentrated under reduced pressure, then acetonitrile was added 
and evaporated to remove most toluene and dried under high vacuum overnight, yielding 
30.509 g crude containing 22.945 g artemisinin according to NMR analysis. Thus a yield of 
65% was achieved at a conversion of 97%. 
The crude was solubilized in 60 mL acetonitrile, activated carbon added and the solution 
refluxed shortly. After cooling down, the carbon was filtrated off with a PTFE syringe filter 
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(0.45 1-1m) and the solvent was removed, yielding 29.735 g of a nearly white solid, as most 
dicyanoanthracene is removed by this procedure. 
The solid was recrystallized from 150 ml cyclohexane:ethanol (9:1 v/v), which yielded off-
white needles. These were filtrated, washed three times with 100 ml cyclohexane each 
and dried under high vacuum (16.515 g, pure artemisinin according to NMR analysis, 47% 
isolated yield, recovery of recrystallization 72%). 
The dried mother liquor (13.288 g) was recrystallized from 50 ml cyclohexane. This 
yielded slightly yellow crystals, which were washed with cyclohexane and dried under high 
vacuum (3.597 g, consisting of artemisinin with 96% purity (3.446 g), isolated yield 10%, 
total combined isolated yield including first recrystallization 57% (87% recovery)). 
Both artemisinin batches were combined and recrystallized from 150 ml 
cyclohexane:ethanol (9:1 v/v), yielding purely white needles, which were filtrated off and 
washed twice with cyclohexane (16.079 g of pure artemisinin, 46% isolated yield based on 
initial dihydroartemisinic acid). 
Example 13: Synthesis of artemisinin (6) in continuous flow using the cooled box 
assembly from plant extract of artemisia annua 
Extraction protocols to remove artemisinic acid and dihydroartemisinic acid from artemisia 
annua have been published (Wallaart, T.E. eta/., J. Nat. Prod. 1999, 62, 430-433), making 
use of the extraction of acidic compounds by aqueous base and the reextraction into an 
organic phase after acidification. An adapted procedure was applied to mother liquor 
remaining after removal of artemisinin from artemisia annua extracts. 20 g of mother liquor 
(containing 8.2% dihydroartemisinic acid according to HPLC analysis) was mixed with 
100 ml diethyl ether and extracted twice with 50 ml 5% aqueous K2C03. The basic 
extract was acidified with cone. HCI to pH 1 and extracted twice with 50 ml diethyl ether. 
The diethyl ether extract was washed once with water, dried over anhydrous Na2S04, the 
solvent removed and the crude dried under high vacuum. A yellow oil remained which 
slowly crystallized (3.653 g). NMR of this basic extract with mesitylene as internal standard 
showed dihydroartemisinic acid (41.8%) and artemisinic acid (7.4%). From the 20 g of raw 
extract, 1.53 g dihydroartemisinic acid could be recovered (7.7% based on initial mother 
liquor, 94% recovery). This enriched extract was used as such without further purification. 
Dicyanoanthracene (14 mg, 0.063 mmol) and trifluoroacetic acid (71 0 mg, 6.23 mmol) was 
added to the extract and the solution filled to 25 ml with toluene (volumetric flask). This 
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mixture was used as feed solution and introduced into the fully continuous process as 
described in example 8. 
The product solution was collected and extracted once with sat. NaHC03 to quench the 
acid, once with 5% K2C03 to extract acidic impurities and then washed with water and 
brine. The organic phase was dried over anhydrous Na2S04 and concentrated under 
reduced pressure, yielding a yellow solid that was dried under high vacuum overnight 
(2.164 g) and contained 1.042 g artemisinin (based on the initial 1.53 g dihydroartemisinic 
acid the crude yield is 57%). The solid was recrystallized from cyclohexane:ethanol (9:1 
v/v). Off-white crystals were obtained, filtered off and washed with cyclohexane. The solid 
was dried under high vacuum (761 mg, 42% isolated yield, pure artemisinin by NMR, 73% 
recovery by recrystallization). 
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Claims 
1. A method for producing artemisinin from dihydroartemisinic acid comprising the 
following steps: 
A) providing dihydroartemisinic acid represented by the following formula 
0 
B) performing in a continuous flow reactor the following reactions 
i) photooxidation of dihydroartemisinic acid with singlet oxygen, 
ii) followed by an acid mediated cleavage, and 
iii) subsequent oxidation with triplet oxygen 
in order to obtain artemisinin of the following formula: 
0 
2. The method according to claim 1, wherein all three steps i), ii) and iii) are performed 
in a continuous manner. 
3. The method according to claim 1 or 2, wherein the photooxidation of step i) is 
carried out under pressure. 
4. The method according to any previous claim, wherein all three steps i) - iii) are 
carried out under pressure. 
5. The method according to any previous claim, wherein the dihydroartemisinic acid is 
obtained by reducing artemisinic acid of the following formula 
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0 
to dihydroartemisinic acid. 
6. The method according to any previous claim, wherein the continuous flow reactor 
comprises a tube made of a fluorinated or perfluorinated alkylene polymer wherein 
the photooxidation of dihydroartemisinic acid takes place. 
7. The method according to any previous claim, wherein trifluoroacetic acid is used for 
the acid mediated cleavage. 
8. The method according to any one of claims 1 - 7, wherein 12.5 mmol 
dihydroartemisinic acid are processed in a total residence time below 5 minutes 
through the continuous flow reactor in order to yield at least 39% artemisinin of a 
purity above 95%. 
9. A photochemical reactor for the production of artemisinin from dihydroartemisinic 
acid comprising 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment exposed to the light source for irradiating the mixture of the 
solution of dihydroartemisinic acid and oxygen when the mixture passes the 
reactor compartment. 
10. The photochemical reactor according to claim 9, wherein the reactor compartment 
is a tubing 7. 
11. The photochemical reactor according to claim 9 or 10, wherein the mixing device is 
aT-mixer valve. 
12. The photochemical reactor according to any one of claims 9 to 11 further 
comprising 
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a box which is impervious to light with light reflecting inner walls and one 
opening through which the tubing 7 enters the box and another opening through 
which the tubing 7 leaves the box and 
multiple loops of the tubing 7 arranged in the inside of the box, wherein the 
tubing 7 has an inlet for a mixture of dihydroartemisinic acid and oxygen on its 
one end before entering the box and an outlet for the reacted products on the 
opposite end after leaving the box. 
13. The photochemical reactor according to any one of claims 9 to 12 further 
comprising 
a cooling liquid and a chiller. 
14. A continuous flow reactor for the production of artemisinin from dihydroartemisinic 
acid comprising: 
a light source 11, 
mixing device for mixing oxygen with a solution of dihydroartemisinic acid, 
reactor compartment exposed to the light source for irradiating the mixture of 
dihydroartemisinic acid and oxygen when the mixture passes the reactor 
compartment, and 
a feed for an acidic solution. 
15. The continuous flow reactor according to claim 14, further comprising 
at least one reactor 15 for producing artemisinin or completing the synthesis of 
artemisinin, 
a collection flask 18 for collecting the artemisinin containing solution from the at 
least one reactor 15. 
16. The continuous flow reactor according to claim 14 or 15, further comprising 
a second reactor 16 downstream to the first reactor 15 or 
a second reactor 16 downstream to the first reactor 15 and a third reactor 17 
downstream to the second reactor 16. 
17. The continuous flow reactor according to any one of claim 14 - 16, further 
comprising 
a back-pressure regulator 14. 
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28: T-type mixer 
oxygen gas 
27: surface of inner box wall 
Figure 5 
29: tubing inlet 
21 : transparent body 
22: wrapped FEP tubing 20: box assembly 
23: LED module 
24: arranged 
LED's 
25: direction of lighting 
26: tubing outlet 
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27: surface of inner box wall 
Figure12 
29: tubing inlet 
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26: tubing outlet 
21: transparent body 
22: wrapped FEP tubing 20: box assembly 
23: LED module 
24: arranged 
LED's 
25: direction of lighting 
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